WJ,O
C,O
C,O
Clinical,O
Cases,O
World,O
J,O
Clin,O
Cases,O
2020,DATE
June,DATE
26,DATE
;,O
8,NUMBER
(,O
12,NUMBER
),O
:,O
2554,DATE
‐,O
2565,DATE
ORIGINAL,O
ARTICLE,O
Prospective,O
Study,O
Epidemiological,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
in,O
Hengyang,CITY
.,O
Hunan,STATE_OR_PROVINCE
Province,O
.,O
China,COUNTRY
Zhe,O
‐,O
Feng,PERSON
Zhong,PERSON
.,O
Jia,PERSON
Huang,PERSON
.,O
Xia,PERSON
Yang,PERSON
.,O
Jin,PERSON
‐,PERSON
Ling,PERSON
Peng,PERSON
.,O
Xiao,PERSON
‐,PERSON
Yan,PERSON
Zhang,PERSON
.,O
Yang,PERSON
Hu,PERSON
.,O
Nian,PERSON
Fu,PERSON
.,O
Hai,PERSON
‐,PERSON
Lian,PERSON
Lin,PERSON
.,O
Bo,PERSON
Jiang,PERSON
.,O
Ya,PERSON
‐,PERSON
Ying,PERSON
Tian,PERSON
.,O
Hong,O
‐,O
Yi,PERSON
Yao,PERSON
.,O
Li,PERSON
‐,PERSON
Pu,PERSON
Deng,PERSON
.,O
Xiao,PERSON
‐,PERSON
Qing,PERSON
Tang,PERSON
.,O
Jie,O
‐,O
Can,O
Zhou,PERSON
.,O
Jian,PERSON
Tang,PERSON
.,O
Xia,PERSON
Xie,PERSON
.,O
Qiong,PERSON
Liu,PERSON
.,O
Jing,PERSON
Liu,PERSON
.,O
Cheng,PERSON
‐,PERSON
Yun,PERSON
Dou,PERSON
.,O
Rong,PERSON
‐,O
Juan,PERSON
Dai,PERSON
.,O
Bo,PERSON
Yan,PERSON
.,O
Xue,O
‐,O
Feng,PERSON
Yang,PERSON
(,O
0000,DATE
‐,O
0001,DATE
‐,O
8938,NUMBER
‐,O
5397,NUMBER
),O
;,O
Jia,PERSON
Huang,PERSON
(,O
0000,DATE
‐,O
0001,DATE
‐,O
8793,NUMBER
‐,O
1075,DATE
),O
;,O
Xia,PERSON
Yang,PERSON
Peng,PERSON
(,O
0000,DATE
‐,O
0002,DATE
‐,O
0685,DATE
‐,O
5881,NUMBER
),O
;,O
XiaoYan,PERSON
Zhang,PERSON
(,O
0000,DATE
‐,O
0003,DATE
‐,O
0598,DATE
‐,O
1525,DATE
),O
;,O
Yang,PERSON
Hu,PERSON
(,O
0000,DATE
‐,O
0003,DATE
‐,O
0042,DATE
‐,O
7146,NUMBER
),O
;,O
Nian,PERSON
Fu,PERSON
(,O
0000,DATE
‐,O
0001,DATE
‐,O
8616,NUMBER
‐,O
453X,O
),O
;,O
HaiLian,PERSON
Lin,PERSON
(,O
0000,DATE
‐,O
0002,DATE
‐,O
2082,DATE
‐,O
0917,DATE
),O
;,O
Bo,PERSON
Jiang,PERSON
(,O
0000,DATE
‐,O
0002,DATE
‐,O
5953,NUMBER
‐,O
8580,NUMBER
),O
;,O
YaYing,O
Tian,PERSON
(,O
0000,DATE
‐,O
0001,DATE
‐,O
6788,NUMBER
‐,O
8911,NUMBER
),O
;,O
Hong,O
‐,O
Yi,PERSON
Yao,PERSON
(,O
0000,DATE
‐,O
0002,DATE
‐,O
3078,NUMBER
‐,O
7719,NUMBER
),O
;,O
Li,PERSON
‐,PERSON
Pu,PERSON
Deng,PERSON
(,O
0000,DATE
‐,O
0003,DATE
‐,O
0698,DATE
‐,O
308X,NUMBER
),O
;,O
Xiao,PERSON
‐,PERSON
Qing,PERSON
Tang,PERSON
(,O
0000,DATE
‐,O
0001,DATE
‐,O
9151,NUMBER
‐,O
3730,NUMBER
),O
;,O
Jie,O
‐,O
Can,O
Zhou,O
(,O
0000,DATE
‐,O
0001,DATE
‐,O
8316,NUMBER
‐,O
3566,NUMBER
),O
;,O
Jian,PERSON
Tang,PERSON
(,O
0000,DATE
‐,O
0002,DATE
‐,O
5050,NUMBER
‐,O
5758,NUMBER
),O
;,O
Xia,PERSON
Xie,PERSON
(,O
0000,DATE
‐,O
0002,DATE
‐,O
2924,DATE
‐,O
2869,DATE
),O
;,O
Qiong,PERSON
Liu,PERSON
(,O
0000,DATE
‐,O
0001,DATE
‐,O
7183,NUMBER
‐,O
5302,NUMBER
),O
;,O
Jing,PERSON
Liu,PERSON
Dou,PERSON
(,O
0000,DATE
‐,O
0002,DATE
‐,O
7376,NUMBER
‐,O
2677,DATE
),O
;,O
RongJuan,PERSON
Dai,PERSON
(,O
0000,DATE
‐,O
0002,DATE
‐,O
5949,NUMBER
‐,O
950X,NUMBER
),O
;,O
Bo,PERSON
Yan,PERSON
(,O
0000,DATE
‐,O
0002,DATE
‐,O
0247,DATE
‐,O
1792,DATE
),O
;,O
XueFeng,PERSON
Yang,PERSON
(,O
0000,DATE
‐,O
0002,DATE
‐,O
3470,NUMBER
‐,O
0350,DATE
),O
.,O
and,O
Huang,PERSON
J,PERSON
equally,O
contrib,O
‐,O
uted,O
to,O
this,O
work,O
;,O
Yang,PERSON
XF,O
and,O
Tang,PERSON
XQ,O
designed,O
the,O
study,O
and,O
edited,O
the,O
LP,O
.,O
Jiang,PERSON
B,O
.,O
Tian,O
YY,O
.,O
Yao,PERSON
HY,PERSON
.,O
Zhou,O
JC,O
.,O
Tang,PERSON
J,PERSON
.,O
Xie,PERSON
X,PERSON
.,O
Liu,PERSON
Q,O
.,O
Liu,PERSON
J,PERSON
.,O
Dou,O
CY,O
.,O
and,O
Dai,PERSON
RJ,PERSON
participated,O
in,O
data,O
collection,O
;,O
Yang,O
X,O
.,O
Peng,PERSON
JL,PERSON
.,O
Zhang,PERSON
XY,PERSON
.,O
Yan,PERSON
B,PERSON
.,O
and,O
Fu,O
N,O
took,O
part,O
in,O
data,O
sorting,O
;,O
Yang,PERSON
XF,O
.,O
Huang,PERSON
J,PERSON
.,O
and,O
Lin,PERSON
HL,O
carried,O
out,O
read,O
and,O
ap,O
‐,O
proved,O
the,O
final,O
Supported,O
by,O
the,O
Novel,O
Coronavirus,O
Pneumonia,CAUSE_OF_DEATH
Zhe,O
‐,O
Feng,PERSON
Zhong,PERSON
.,O
Bo,PERSON
Jiang,PERSON
.,O
Ya,O
‐,O
Ying,PERSON
Tian,PERSON
.,O
Department,O
of,O
Infectious,O
Diseases,CAUSE_OF_DEATH
.,O
the,O
Afliated,LOCATION
Hunan,STATE_OR_PROVINCE
Province,LOCATION
.,O
China,COUNTRY
Jia,PERSON
Huang,PERSON
.,O
Yang,PERSON
Hu,PERSON
.,O
Nian,PERSON
Fu,PERSON
.,O
Hai,PERSON
‐,PERSON
Lian,PERSON
Lin,PERSON
.,O
Xue,PERSON
‐,PERSON
Feng,PERSON
Yang,PERSON
.,O
Department,O
of,O
Gastroen,O
‐,O
terology,O
.,O
the,O
421002,NUMBER
.,O
Hunan,STATE_OR_PROVINCE
Province,LOCATION
.,O
China,COUNTRY
Xia,PERSON
Yang,PERSON
.,O
Jin,PERSON
‐,PERSON
Ling,PERSON
Peng,PERSON
.,O
Xiao,PERSON
‐,PERSON
Yan,PERSON
Zhang,PERSON
.,O
Department,ORGANIZATION
of,ORGANIZATION
General,ORGANIZATION
Practice,ORGANIZATION
.,O
the,O
Afliat,O
‐,O
ed,O
Hunan,STATE_OR_PROVINCE
Province,LOCATION
.,O
China,COUNTRY
Hong,O
‐,O
Yi,PERSON
Yao,PERSON
.,O
Li,PERSON
‐,PERSON
Pu,PERSON
Deng,PERSON
.,O
Department,O
of,O
Intensive,O
Medicine,O
.,O
the,O
Afliated,ORGANIZATION
Nanhua,ORGANIZATION
Hospital,ORGANIZATION
.,O
Jie,O
‐,O
Can,O
Zhou,PERSON
.,O
Jian,PERSON
Tang,PERSON
.,O
Xia,PERSON
Xie,PERSON
.,O
Qiong,PERSON
Liu,PERSON
.,O
Jing,PERSON
Liu,PERSON
.,O
Cheng,PERSON
‐,PERSON
Yun,PERSON
Dou,PERSON
.,O
Rong,PERSON
‐,PERSON
Juan,PERSON
Dai,PERSON
.,O
Department,O
of,O
Infectious,O
Diseases,CAUSE_OF_DEATH
.,O
the,O
First,ORDINAL
Affiliated,O
Hos,O
‐,O
pital,O
.,O
Hengyang,ORGANIZATION
Medical,ORGANIZATION
College,ORGANIZATION
.,O
Bo,PERSON
Yan,PERSON
.,O
Department,O
of,O
Cardiolo,O
‐,O
gy,O
.,O
the,O
First,ORGANIZATION
Affiliated,ORGANIZATION
Hospital,ORGANIZATION
.,O
Hengyang,ORGANIZATION
Medical,ORGANIZATION
College,ORGANIZATION
.,O
336,NUMBER
.,O
Dongfeng,CITY
Road,LOCATION
.,O
Zhuhui,LOCATION
District,LOCATION
.,O
Hengyang,CITY
421002,NUMBER
.,O
Hunan,STATE_OR_PROVINCE
Province,LOCATION
.,O
China,COUNTRY
.,O
In,O
December,DATE
2019,DATE
.,O
an,O
ongoing,O
outbreak,O
of,O
coronavirus,O
dis,O
‐,O
ease,O
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
was,O
first,ORDINAL
identified,O
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
The,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
treated,O
in,O
local,O
hospitals,O
in,O
Wuhan,CITY
are,O
not,O
fully,O
representative,TITLE
of,O
patients,O
outside,O
Wuhan,CITY
.,O
Therefore,O
.,O
it,O
is,O
highly,O
essential,O
to,O
analyze,O
the,O
epidemiological,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
in,O
areas,O
outside,O
Wuhan,CITY
or,O
Hubei,STATE_OR_PROVINCE
Province,LOCATION
.,O
To,O
date,O
.,O
a,O
limited,O
number,O
of,O
studies,O
have,O
concentrated,O
on,O
the,O
epidemiological,O
Zhong,O
ZF,O
et,O
al,O
.,O
Epidemiologi,O
‐,O
cal,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
South,LOCATION
China,COUNTRY
.,O
No,O
.,O
2020,DATE
‐,O
15,NUMBER
and,O
No,O
.,O
2020,DATE
‐,O
25,NUMBER
;,O
the,O
Hengyang,ORGANIZATION
Science,ORGANIZATION
and,ORGANIZATION
Technology,ORGANIZATION
Plan,O
Project,O
‐,O
Basic,O
Research,O
Project,O
of,O
Prevention,O
and,O
Treatment,O
of,O
the,O
Novel,O
Coronavirus,O
Pneumonia,CAUSE_OF_DEATH
.,O
No,O
.,O
202010031577,NUMBER
;,O
the,O
Scien,O
‐,O
tific,ORGANIZATION
Research,ORGANIZATION
Project,ORGANIZATION
of,ORGANIZATION
Hunan,ORGANIZATION
Provincial,ORGANIZATION
Health,ORGANIZATION
and,O
Family,O
Planning,ORGANIZATION
Commission,ORGANIZATION
.,O
No,O
.,O
A2017015,O
;,O
the,O
Natural,O
Science,O
Founda,O
‐,O
tion,O
of,O
Hunan,STATE_OR_PROVINCE
Province,LOCATION
.,O
China,COUNTRY
.,O
No.,O
2016JJ5010,O
;,O
and,O
the,O
National,O
Natural,ORGANIZATION
Science,ORGANIZATION
Foundation,ORGANIZATION
of,ORGANIZATION
China,ORGANIZATION
.,O
No,O
.,O
statement,O
:,O
The,O
study,O
was,O
conducted,O
in,O
accordance,O
with,O
the,O
Declaration,O
of,O
Helsinki,CITY
.,O
and,O
it,O
was,O
approved,O
by,O
the,O
Ethics,ORGANIZATION
Committee,ORGANIZATION
of,ORGANIZATION
Afliated,ORGANIZATION
Nanhua,ORGANIZATION
Hospi,ORGANIZATION
‐,O
tal,O
of,O
Clinical,O
trial,O
registration,O
statement,O
:,O
This,O
study,O
is,O
not,O
a,O
clinical,O
trial,O
Informed,O
consent,O
statement,O
:,O
All,O
the,O
patients,O
signed,O
a,O
written,O
informed,O
consent,O
form,O
prior,O
to,O
commencing,O
the,O
study,O
.,O
Conflict,O
‐,O
of,O
‐,O
interest,O
statement,O
:,O
All,O
conflict,O
of,O
interest,O
.,O
Data,O
sharing,O
statement,O
:,O
No,O
additional,O
data,O
are,O
available,O
.,O
dis,O
‐,O
tribute,O
.,O
remix,O
.,O
adapt,O
.,O
build,O
on,O
different,O
terms,O
.,O
provided,O
the,O
original,O
work,O
is,O
properly,O
cited,O
and,O
First,ORDINAL
decision,O
:,O
March,DATE
27,DATE
.,O
2020,DATE
Revised,O
:,O
May,DATE
15,DATE
.,DATE
2020,DATE
Shen,O
HN,O
.,O
Yu,O
B,O
and,O
clinical,O
character,O
‐,O
istics,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
with,O
different,O
genders,O
.,O
clinical,O
classification,O
.,O
and,O
with,O
or,O
without,O
basic,O
diseases,CAUSE_OF_DEATH
.,O
To,O
study,O
the,O
epidemiological,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
in,O
Hengyang,CITY
(,O
China,COUNTRY
),O
and,O
provide,O
a,O
reliable,O
reference,O
for,O
the,O
pre,O
‐,O
vention,O
and,O
control,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
From,O
January,DATE
16,DATE
to,O
March,DATE
2,DATE
.,O
2020,DATE
.,O
a,O
total,O
of,O
48,NUMBER
confirmed,O
cases,O
of,O
COVID,O
‐,O
19,NUMBER
were,O
reported,O
in,O
Hengyang,CITY
.,O
and,O
those,O
cases,O
were,O
included,O
in,O
this,O
study,O
.,O
The,O
diag,O
‐,O
nostic,O
criteria,O
.,O
clinical,O
classification,O
.,O
and,O
discharge,O
standard,O
related,O
to,O
COVID,O
‐,O
19,NUMBER
were,O
in,O
line,O
with,O
the,O
Diagnosis,MISC
and,O
Treatment,O
Protocol,O
for,O
Novel,O
Coronavirus,O
Pneumonia,CAUSE_OF_DEATH
(,O
Trial,O
Version,O
7,NUMBER
),O
re,O
‐,O
leased,O
by,O
National,ORGANIZATION
Health,ORGANIZATION
Commission,ORGANIZATION
and,O
National,ORGANIZATION
Administration,ORGANIZATION
of,O
Traditional,O
Chinese,NATIONALITY
Medicine,O
.,O
The,O
presence,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
pharyngeal,O
swab,O
specimens,O
was,O
detected,O
by,O
quantitative,O
reverse,O
transcription,O
polymerase,O
chain,O
reaction,O
.,O
All,O
the,O
data,O
were,O
im,O
‐,O
ported,O
into,O
the,O
excel,O
worksheet,O
and,O
statistically,O
analyzed,O
by,O
us,O
‐,O
ing,O
SPSS,ORGANIZATION
25.0,NUMBER
A,O
total,O
of,O
48,NUMBER
cases,O
of,O
COVID,O
‐,O
19,NUMBER
were,O
collected,O
.,O
of,O
which,O
1,NUMBER
was,O
mild,O
.,O
38,NUMBER
were,O
moderate,O
.,O
and,O
9,NUMBER
were,O
severe,O
.,O
It,O
was,O
un,O
‐,O
veiled,O
that,O
there,O
were,O
31,NUMBER
(,O
64.6,PERCENT
%,PERCENT
),O
male,O
patients,O
and,O
17,NUMBER
(,O
35.4,PERCENT
%,PERCENT
),O
female,O
patients,O
.,O
with,O
a,O
female,O
‐,O
to,O
‐,O
male,O
ratio,O
of,O
1.82:1,O
.,O
The,O
range,O
of,O
age,O
of,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
was,O
dominantly,O
30,NUMBER
‐,O
49,DURATION
years,DURATION
old,DURATION
[,O
25,NUMBER
(,O
52.1,PERCENT
%,PERCENT
),O
of,O
48,NUMBER
],O
.,O
followed,O
by,O
those,O
aged,O
over,O
60,DURATION
years,DURATION
old,DURATION
[,O
11,NUMBER
(,O
22.9,PERCENT
%,PERCENT
),O
],O
.,O
Besides,O
.,O
29.2,PERCENT
%,PERCENT
(,O
14,NUMBER
of,O
48,NUMBER
),O
of,O
patients,O
had,O
basic,O
dis,O
‐,O
eases,O
.,O
and,O
57.2,PERCENT
%,PERCENT
(,O
8,NUMBER
of,O
14,NUMBER
),O
of,O
patients,O
with,O
basic,O
diseases,CAUSE_OF_DEATH
were,O
aged,O
over,O
60,DURATION
years,DURATION
old,DURATION
.,O
The,O
occupations,O
of,O
48,NUMBER
COVID,O
‐,O
19,NUMBER
patients,O
were,O
mainly,O
farmers,O
working,O
in,O
agricultural,O
production,O
[,O
15,NUMBER
(,O
31.5,PERCENT
%,PERCENT
),O
of,O
48,NUMBER
],O
.,O
rural,O
migrant,O
workers,O
from,O
Hengyang,CITY
to,O
Wuhan,CITY
[,O
15,NUMBER
(,O
31.5,PERCENT
%,PERCENT
),O
],O
.,O
and,O
service,O
workers,O
operating,O
in,O
the,O
service,O
sector,O
[,O
8,NUMBER
(,O
16.7,PERCENT
%,PERCENT
),O
],O
.,O
The,O
mean,O
latent,O
period,O
was,O
6.86,NUMBER
3.57,NUMBER
d,O
.,O
and,O
the,O
median,O
was,O
7,NUMBER
[,O
interquartile,O
range,O
(,O
IQR,O
),O
:,O
4,NUMBER
‐,O
9,NUMBER
],O
d,O
.,O
The,O
mean,O
time,O
from,O
on,O
‐,O
set,O
of,O
symptoms,O
to,O
the,O
first,ORDINAL
physician,TITLE
visit,O
was,O
3.38,NUMBER
2.98,NUMBER
(,O
95,PERCENT
%,PERCENT
CI,O
:,O
2.58,NUMBER
‐,O
9.18,NUMBER
),O
d,O
.,O
with,O
a,O
median,O
of,O
2,NUMBER
(,O
IQR,O
:,O
1,NUMBER
‐,O
5,NUMBER
),O
d,O
.,O
and,O
the,O
mean,O
time,O
from,O
hospital,O
admission,O
to,O
confirmed,O
diagnosis,O
was,O
2.29,NUMBER
2.11,NUMBER
(,O
95,PERCENT
%,PERCENT
CI,O
:,O
1.18,NUMBER
‐,O
6.42,NUMBER
),O
d,O
.,O
with,O
a,O
median,O
of,O
2,NUMBER
(,O
IQR,O
:,O
1,NUMBER
‐,O
3,NUMBER
),O
d.,O
The,O
main,O
symptoms,O
were,O
fever,CAUSE_OF_DEATH
[,O
43,NUMBER
(,O
89.6,PERCENT
%,PERCENT
),O
of,O
48,NUMBER
],O
.,O
cough,O
and,O
expectora,O
‐,O
tion,O
[,O
41,NUMBER
(,O
85.4,PERCENT
%,PERCENT
),O
],O
.,O
fatigue,O
[,O
22,NUMBER
(,O
45.8,PERCENT
%,PERCENT
),O
],O
.,O
and,O
chills,O
[,O
22,NUMBER
(,O
45.8,PERCENT
%,PERCENT
),O
],O
.,O
Other,O
symptoms,O
included,O
poor,O
appetite,O
[,O
13,NUMBER
(,O
27.1,PERCENT
%,PERCENT
),O
],O
.,O
sore,O
throat,O
[,O
9,NUMBER
(,O
18.8,PERCENT
%,PERCENT
),O
],O
.,O
dyspnea,O
[,O
9,NUMBER
(,O
18.8,PERCENT
%,PERCENT
),O
],O
.,O
diarrhea,O
[,O
7,NUMBER
(,O
14.6,PERCENT
%,PERCENT
),O
],O
.,O
dizziness,O
[,O
5,NUMBER
(,O
10.4,PERCENT
%,PERCENT
),O
],O
.,O
headache,O
[,O
5,NUMBER
(,O
10.4,PERCENT
%,PERCENT
),O
],O
.,O
muscle,O
pain,O
[,O
5,NUMBER
(,O
10.4,PERCENT
%,PERCENT
),O
],O
.,O
nau,O
‐,O
sea,O
and,O
vomiting,O
[,O
4,NUMBER
(,O
8.3,PERCENT
%,PERCENT
),O
],O
.,O
hemoptysis,O
[,O
4,NUMBER
(,O
8.3,PERCENT
%,PERCENT
),O
],O
.,O
and,O
runny,O
nose,O
[,O
1,NUMBER
(,O
2.1,PERCENT
%,PERCENT
),O
],O
.,O
The,O
numbers,O
of,O
peripheral,O
blood,O
leukocytes,O
.,O
lym,O
‐,O
phocytes,O
.,O
and,O
eosinophils,O
were,O
significantly,O
reduced,O
in,O
the,O
ma,O
‐,O
jority,O
of,O
the,O
patients,O
.,O
The,O
levels,O
of,O
C,O
‐,O
reactive,O
protein,O
.,O
fib,O
‐,O
rinogen,O
.,O
blood,O
glucose,O
.,O
lactate,O
dehydrogenase,O
.,O
Ddimer,O
.,O
alanine,O
aminotransferase,O
(,O
ALT,O
),O
.,O
aspartate,O
aminotransferase,O
(,O
AST,O
),O
.,O
gamma,O
‐,O
glutamyl,O
transferase,O
(,O
‐,O
GT,O
),O
.,O
myoglobin,O
(,O
MB,STATE_OR_PROVINCE
),O
.,O
and,O
creatine,O
kinase,O
(,O
CK,O
),O
were,O
increased,O
in,O
64.6,PERCENT
%,PERCENT
.,O
44.7,PERCENT
%,PERCENT
.,O
43.2,PERCENT
%,PERCENT
.,O
37.0,PERCENT
%,PERCENT
.,O
29.5,PERCENT
%,PERCENT
.,O
22.9,PERCENT
%,PERCENT
.20.8,PERCENT
%,PERCENT
.,O
21.6,PERCENT
%,PERCENT
.,O
13.6,PERCENT
%,PERCENT
.,O
and,O
12.8,PERCENT
%,PERCENT
of,O
patients,O
.,O
respectively,O
.,O
The,O
incidence,O
of,O
ALT,O
elevation,O
in,O
male,O
patients,O
was,O
remarkably,O
higher,O
than,O
that,O
in,O
females,O
(,O
P,O
<,O
0.01,NUMBER
),O
.,O
while,O
the,O
incidences,O
of,O
AST,ORGANIZATION
.,O
CK,O
.,O
and,O
blood,O
glucose,O
elevations,O
in,O
severe,O
patients,O
were,O
re,O
‐,O
markably,O
higher,O
than,O
those,O
in,O
moderate,O
patients,O
(,O
P,O
<,O
0.05,NUMBER
.,O
re,O
‐,O
spectively,O
),O
.,O
Except,O
for,O
the,O
mild,O
patients,O
.,O
chest,O
computed,O
tomog,O
‐,O
raphy,O
showed,O
characteristic,O
pulmonary,O
lesions,O
.,O
All,O
the,O
patients,O
received,O
antiviral,O
drugs,CRIMINAL_CHARGE
.,O
38,NUMBER
(,O
79.2,PERCENT
%,PERCENT
),O
accepted,O
traditional,O
Chinese,NATIONALITY
medicine,O
.,O
and,O
2,NUMBER
(,O
4.2,PERCENT
%,PERCENT
),O
received,O
treatment,O
of,O
human,O
umbilical,O
‐,O
cord,O
mesenchymal,O
stem,O
cells,O
.,O
On,O
March,DATE
2,DATE
.,DATE
2020,DATE
.,O
48,NUMBER
patients,O
with,O
COVID,O
‐,O
19,NUMBER
were,O
all,O
cured,O
and,O
discharged,O
.,O
Based,O
on,O
our,O
results,O
.,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
often,O
have,O
multiple,O
organ,O
dysfunction,O
or,O
damage,O
.,O
The,O
incidences,O
of,O
ALT,O
elevation,O
in,O
males,O
.,O
and,O
AST,ORGANIZATION
.,O
CK,O
.,O
and,O
blood,O
glucose,O
elevations,O
in,O
severe,O
patients,O
are,O
remarkably,O
higher,O
.,O
Key,O
words,O
:,O
Novel,O
coronavirus,O
pneumonia,CAUSE_OF_DEATH
;,O
COVID,O
‐,O
19,NUMBER
;,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
;,O
Epidemiology,O
;,O
Hengyang,CITY
;,O
Coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
Zhong,PERSON
ZF,PERSON
et,O
al,O
.,O
Epidemiological,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
Core,O
tip,O
:,O
To,O
study,O
the,O
epidemiological,O
and,O
clinical,O
characteris,O
‐,O
tics,O
of,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
patients,O
with,O
differ,O
‐,O
ent,O
genders,O
.,O
clinical,O
classification,O
.,O
and,O
with,O
or,O
without,O
basic,O
diseases,CAUSE_OF_DEATH
could,O
provide,O
more,O
information,O
for,O
COVID,O
‐,O
19,NUMBER
prevention,O
and,O
control,O
.,O
Our,O
research,O
found,O
that,O
many,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
had,O
multiple,O
organ,O
dysfunction,O
or,O
damage,O
.,O
The,O
higher,O
attention,O
of,O
the,O
government,O
and,O
residents,O
on,O
the,O
prevention,O
and,O
control,O
of,O
COVID,O
‐,O
19,NUMBER
was,O
the,O
key,O
factor,O
to,O
control,O
the,O
development,O
of,O
COVID,O
‐,O
19,NUMBER
epidemic,O
.,O
Wearing,O
masks,O
and,O
home,O
isolation,O
could,O
effec,O
‐,O
tively,O
cut,O
off,O
transmission,O
routes,O
and,O
prevent,O
the,O
spread,O
of,O
the,O
novel,O
coronavirus,O
.,O
Citation,O
:,O
Zhong,PERSON
ZF,PERSON
.,O
Huang,PERSON
J,PERSON
.,O
Yang,PERSON
X,O
.,O
Peng,O
JL,O
.,O
Zhang,PERSON
XY,PERSON
.,O
Hu,O
Y,O
.,O
Fu,O
N,O
.,O
Lin,O
HL,O
.,O
Jiang,PERSON
B,O
.,O
Tian,O
YY,O
.,O
Yao,PERSON
HY,PERSON
.,O
Deng,PERSON
LP,O
.,O
Tang,O
XQ,O
.,O
Zhou,PERSON
JC,PERSON
.,O
Tang,PERSON
J,PERSON
.,O
Xie,PERSON
X,PERSON
.,O
Liu,PERSON
Q,O
.,O
Liu,PERSON
J,PERSON
.,O
Dou,O
CY,O
.,O
Dai,PERSON
RJ,PERSON
.,O
Yan,O
B,O
.,O
Yang,PERSON
XF,O
.,O
Epidemiological,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
in,O
Hengyang,CITY
.,O
Hunan,STATE_OR_PROVINCE
Province,LOCATION
.,O
China,COUNTRY
.,O
World,O
J,O
Clin,O
Cases,O
2020,DATE
;,O
8,NUMBER
(,O
12,NUMBER
),O
:,O
2554,DATE
‐,O
2565,DATE
On,O
December,DATE
31,DATE
.,DATE
2019,DATE
.,O
an,O
unex,O
‐,O
plained,O
pneumonia,CAUSE_OF_DEATH
was,O
reported,O
in,O
Wuhan,CITY
.,O
China,COUNTRY
[,O
1,NUMBER
],O
.,O
It,O
was,O
found,O
that,O
this,O
pneumonia,CAUSE_OF_DEATH
was,O
caused,O
by,O
a,O
2019,DATE
novel,O
coronavirus,O
(,O
2019nCoV,O
),O
[,O
2,NUMBER
],O
.,O
which,O
was,O
named,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,NUMBER
(,O
SARSCoV,O
‐,O
2,NUMBER
),O
by,O
the,O
International,ORGANIZATION
Committee,ORGANIZATION
on,O
Tax,O
‐,O
onomy,O
of,O
Viruses,O
.,O
The,O
disease,CAUSE_OF_DEATH
caused,O
by,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
was,O
called,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
[,O
3,NUMBER
],O
.,O
COVID,O
‐,O
19,NUMBER
in,O
Wuhan,CITY
.,O
and,O
even,O
throughout,O
mainland,O
China,COUNTRY
;,O
however,O
.,O
from,O
the,O
geographical,O
perspective,O
.,O
the,O
data,O
were,O
mainly,O
from,O
the,O
epidemic,O
centers,O
of,O
Hubei,STATE_OR_PROVINCE
Province,LOCATION
.,O
especially,O
Wuhan,CITY
[,O
4.5,NUMBER
],O
.,O
However,O
.,O
the,O
characteris,O
‐,O
tics,O
of,O
patients,O
treated,O
in,O
local,O
hospitals,O
in,O
Wuhan,CITY
are,O
not,O
ful,O
‐,O
ly,O
representative,TITLE
of,O
patients,O
outside,O
Wuhan,CITY
.,O
Therefore,O
.,O
it,O
is,O
highly,O
essential,O
to,O
analyze,O
the,O
epidemiological,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
in,O
areas,O
outside,O
Wuhan,CITY
or,O
Hubei,STATE_OR_PROVINCE
Prov,O
‐,O
ince,O
.,O
At,O
the,O
same,O
time,O
.,O
there,O
have,O
been,O
limited,O
reports,O
about,O
the,O
differences,O
in,O
the,O
epidemiological,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
with,O
different,O
genders,O
.,O
clinical,O
classifica,O
‐,O
tion,O
.,O
and,O
with,O
or,O
without,O
basic,O
diseases,CAUSE_OF_DEATH
.,O
Since,O
the,O
first,ORDINAL
COVID,O
‐,O
19,NUMBER
patient,O
was,O
discovered,O
on,O
January,DATE
16,DATE
.,DATE
2020,DATE
.,O
a,O
total,O
of,O
48,NUMBER
confirmed,O
cases,O
of,O
COVID,O
‐,O
19,NUMBER
have,O
been,O
reported,O
in,O
Hengyang,CITY
(,O
Hunan,STATE_OR_PROVINCE
Province,LOCATION
),O
.,O
a,O
close,O
neighbor,O
city,O
of,O
Hubei,STATE_OR_PROVINCE
.,O
Until,O
18:00,TIME
on,O
March,DATE
2,DATE
.,DATE
2020,DATE
.,O
all,O
the,O
48,NUMBER
confirmed,O
cases,O
were,O
cured,O
and,O
dis,O
‐,O
charged,O
.,O
At,O
present,DATE
.,O
COVID,O
‐,O
19,NUMBER
is,O
affecting,O
many,O
countries,O
and,O
territories,O
worldwide,O
[,O
6,NUMBER
],O
.,O
The,O
present,DATE
study,O
aimed,O
to,O
summarize,O
the,O
epidemiological,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
pa,O
‐,O
tients,O
in,O
Hengyang,CITY
(,O
China,COUNTRY
),O
and,O
provide,O
a,O
reliable,O
reference,O
for,O
the,O
prevention,O
and,O
control,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
MATERIALS,O
AND,O
METHODS,O
Patients,O
with,O
COVID,O
‐,O
19,NUMBER
According,O
to,O
the,O
arrangements,O
by,O
the,O
Hengyang,CITY
Municipal,O
People,O
’s,O
Government,O
.,O
all,O
the,O
COVID,O
‐,O
19,NUMBER
patients,O
were,O
admitted,O
centrally,O
to,O
the,O
Affiliated,O
Nanhua,LOCATION
Hospital,LOCATION
of,O
South,LOCATION
China,COUNTRY
without,O
selectivity,O
.,O
From,O
January,DATE
16,DATE
to,O
March,DATE
2,DATE
.,O
2020,DATE
.,O
all,O
the,O
48,NUMBER
patients,O
with,O
COVID,O
‐,O
19,NUMBER
who,O
were,O
treated,O
at,O
these,O
two,NUMBER
hospitals,O
were,O
included,O
in,O
the,O
current,DATE
Epidemiological,O
inves,O
‐,O
tigation,O
According,O
to,O
the,O
Diagnosis,MISC
and,O
Treatment,O
Protocol,O
for,O
Novel,O
Coronavirus,O
Pneumonia,CAUSE_OF_DEATH
(,O
Trial,O
Version,O
7,NUMBER
),O
released,O
by,O
Nation,O
‐,O
al,ORGANIZATION
Health,ORGANIZATION
Commission,ORGANIZATION
and,O
National,ORGANIZATION
Administration,ORGANIZATION
of,ORGANIZATION
Traditional,ORGANIZATION
Chinese,NATIONALITY
Medicine,O
[,O
7,NUMBER
],O
.,O
the,O
epidemiological,O
history,O
can,O
be,O
divided,O
into,O
the,O
following,O
five,NUMBER
conditions,O
:,O
(,O
1,NUMBER
),O
History,O
of,O
travel,O
to,O
or,O
residency,O
in,O
an,O
epidemic,O
area,O
within,O
14,NUMBER
d,O
prior,O
to,O
onset,O
of,O
ill,O
‐,O
ness,O
;,O
(,O
2,NUMBER
),O
History,O
of,O
contact,O
with,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
within,O
14,NUMBER
d,O
before,O
onset,O
;,O
(,O
3,NUMBER
),O
History,O
of,O
contact,O
with,O
patients,O
with,O
fever,CAUSE_OF_DEATH
or,O
respiratory,O
symptoms,O
from,O
epidemic,O
areas,O
within,O
14,NUMBER
d,O
prior,O
to,O
onset,O
;,O
(,O
4,NUMBER
),O
Zhong,ORGANIZATION
ZF,ORGANIZATION
et,O
al,O
.,O
Epidemiological,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
Agglomeration,O
;,O
and,O
(,O
5,NUMBER
),O
An,O
unclear,O
epidemic,O
history,O
.,O
Diagnosis,O
and,O
treatment,O
The,O
diagnostic,O
crite,O
‐,O
ria,O
.,O
clinical,O
classification,O
.,O
and,O
discharge,O
standard,O
related,O
to,O
COVID,O
‐,O
19,NUMBER
were,O
in,O
line,O
with,O
the,O
Diagnosis,MISC
and,O
Treatment,O
Protocol,O
for,O
Novel,O
Coronavirus,O
Pneumonia,CAUSE_OF_DEATH
(,O
Trial,O
Version,O
7,NUMBER
),O
[,O
7,NUMBER
],O
.,O
The,O
pres,O
‐,O
ence,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
pharyngeal,O
swab,O
specimens,O
was,O
detected,O
by,O
quantitative,O
reverse,O
transcription,O
polymerase,O
chain,O
reaction,O
(,O
PCR,O
),O
.,O
The,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
nucleic,O
acid,O
diagnostic,O
kit,O
(,O
PCR,O
‐,O
Fluores,O
‐,O
cence,O
Probing,O
),O
was,O
provided,O
by,O
Hunan,PERSON
Shengxiang,PERSON
Biotechnology,PERSON
Co.,ORGANIZATION
.,ORGANIZATION
Ltd.,ORGANIZATION
(,O
Changsha,LOCATION
.,O
China,COUNTRY
),O
.,O
This,O
test,O
utilizes,O
the,O
2019nCoV,O
ORF,O
1ab,O
and,O
the,O
specific,O
conserved,O
sequence,O
of,O
the,O
gene,O
coding,O
for,O
nucleocapsid,O
protein,O
N,O
as,O
the,O
target,O
regions,O
.,O
which,O
were,O
designed,O
for,O
the,O
conserved,O
sequence,O
of,O
the,O
double,O
‐,O
target,O
genes,O
.,O
in,O
order,O
to,O
detect,O
sample,O
RNA,O
through,O
fluorescent,O
signal,O
changes,O
.,O
The,O
se,O
‐,O
quences,O
are,O
:,O
Target,O
1,NUMBER
(,O
ORF1ab,O
),O
[,O
8,NUMBER
],O
:,O
Forward,O
primer,O
.,O
CCCTGTGGGTTT,O
‐,O
TACACTTAA,O
and,O
reverse,O
primer,O
.,O
ACGATTGTGCATCAGCTGA,LOCATION
.,O
and,O
the,O
probe,O
5,NUMBER
‐,O
VIC,O
‐,O
CCGTCTGCGGTATGTGGAAAGGTTATGBHQG,O
‐,O
1,NUMBER
‐,O
3,NUMBER
;,O
Target,O
2,NUMBER
(,O
N,O
),O
[,O
8,NUMBER
],O
:,O
Forward,O
primer,O
.,O
GGGGAACTTCTCCTGCTAGAAT,O
and,O
reverse,O
primer,O
.,O
CAGA,O
‐,O
CATTTTGCTCTCAAGCTG,O
.,O
and,O
the,O
probe,O
5,NUMBER
‐,O
FAM,O
‐,O
TTGCTGCTGCTTGACAGATT,O
‐,O
TAM,O
‐,O
RA,O
‐,O
3,NUMBER
.,O
Conditions,O
for,O
the,O
amplifications,O
were,O
50C,O
for,O
30,DURATION
min,DURATION
.,O
95C,O
for,O
1,DURATION
min,DURATION
.,O
followed,O
by,O
45,NUMBER
cycles,O
of,O
95C,O
for,O
15,NUMBER
s,O
and,O
60C,O
for,O
30,NUMBER
s,O
.,O
The,O
patients,O
diagnosed,O
with,O
COVID,O
‐,O
19,NUMBER
were,O
positive,O
for,O
the,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
nucleic,O
acid,O
test,O
.,O
and,O
all,O
the,O
patients,O
released,O
from,O
isolation,O
and,O
discharged,O
from,O
hospital,O
were,O
tested,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
nucleic,O
acid,O
at,O
least,O
twice,O
.,O
All,O
the,O
patients,O
received,O
antivi,O
‐,O
ral,O
.,O
traditional,O
Chinese,NATIONALITY
medicine,O
(,O
TCM,ORGANIZATION
),O
.,O
and,O
symptomatic,O
therapy,O
according,O
to,O
the,O
Diagnosis,MISC
and,O
Treatment,O
Protocol,O
for,O
Novel,O
Coro,O
‐,O
navirus,O
Pneumonia,CAUSE_OF_DEATH
(,O
Trial,O
Version,O
7,NUMBER
),O
[,O
7,NUMBER
],O
.,O
Statistical,O
analysis,O
The,O
patients,O
data,O
were,O
collected,O
or,O
supplemented,O
by,O
interviews,O
with,O
patients,O
and,O
relatives,O
.,O
and,O
all,O
the,O
data,O
(,O
including,O
epidemiologi,O
‐,O
cal,O
.,O
demographic,O
.,O
clinical,O
.,O
laboratory,O
.,O
treatment,O
.,O
and,O
outcome,O
data,O
),O
were,O
imported,O
into,O
an,O
excel,O
worksheet,O
and,O
statistically,O
an,O
‐,O
alyzed,O
by,O
using,O
SPSS,ORGANIZATION
25.0,NUMBER
software,O
(,O
IBM,ORGANIZATION
.,O
Armonk,LOCATION
.,O
NY,STATE_OR_PROVINCE
.,O
United,PERSON
States,O
),O
.,O
All,O
the,O
data,O
were,O
checked,O
by,O
two,NUMBER
physicians,O
(,O
Huang,PERSON
J,PERSON
and,O
Lin,O
HL,O
),O
.,O
and,O
any,O
difference,O
in,O
interpretation,O
between,O
the,O
two,NUMBER
physicians,O
was,O
adjudicated,O
by,O
a,O
third,ORDINAL
researcher,TITLE
(,O
Yang,PERSON
XF,O
),O
.,O
Nu,O
‐,O
merical,O
variables,O
are,O
described,O
using,O
the,O
mean,O
SD,STATE_OR_PROVINCE
.,O
95,PERCENT
%,PERCENT
confi,O
‐,O
dence,O
interval,O
(,O
95,PERCENT
%,PERCENT
CI,O
),O
.,O
median,O
.,O
and,O
interquartile,O
range,O
(,O
IQR,O
),O
values,O
.,O
Categorical,O
variables,O
are,O
described,O
as,O
percentages,O
and,O
were,O
compared,O
using,O
the,O
2,NUMBER
test,O
.,O
P,O
<,O
0.05,NUMBER
was,O
considered,O
statis,O
‐,O
tically,O
significant,O
.,O
Patients,O
demographic,O
characteristics,O
A,O
to,O
‐,O
tal,O
of,O
48,NUMBER
cases,O
of,O
COVID,O
‐,O
19,NUMBER
were,O
collected,O
.,O
of,O
which,O
1,NUMBER
was,O
mild,O
.,O
38,NUMBER
were,O
moderate,O
.,O
and,O
9,NUMBER
were,O
severe,O
.,O
The,O
mean,O
age,O
of,O
the,O
48,NUMBER
pa,O
‐,O
tients,O
was,O
44.35,NUMBER
15.76,NUMBER
(,O
95,PERCENT
%,PERCENT
CI,O
:,O
3.42,NUMBER
‐,O
48.24,NUMBER
),O
years,DURATION
old,O
.,O
and,O
the,O
median,O
age,O
was,O
41,NUMBER
(,O
IQR,O
:,O
34.75,NUMBER
‐,O
53.75,NUMBER
),O
years,DURATION
old,O
;,O
for,O
moderate,O
cas,O
‐,O
es,O
.,O
the,O
mean,O
age,O
was,O
43.95,NUMBER
16.24,NUMBER
(,O
95,PERCENT
%,PERCENT
CI,O
:,O
12.64,NUMBER
‐,O
75.36,NUMBER
),O
years,DURATION
old,O
.,O
and,O
the,O
median,O
age,O
was,O
41,NUMBER
(,O
IQR,O
:,O
11.64,NUMBER
‐,O
74.36,NUMBER
),O
years,DURATION
old,O
;,O
for,O
se,O
‐,O
vere,O
cases,O
.,O
the,O
mean,O
age,O
was,O
49.11,NUMBER
13.45,NUMBER
(,O
95,PERCENT
%,PERCENT
CI,O
:,O
22.54,NUMBER
‐,O
75.46,NUMBER
),O
years,DURATION
old,O
.,O
and,O
the,O
median,O
age,O
was,O
47,NUMBER
(,O
IQR,O
:,O
38,NUMBER
‐,O
65,NUMBER
),O
years,DURATION
old,O
.,O
Among,O
all,O
the,O
patients,O
.,O
the,O
maximum,O
and,O
minimum,O
ages,O
were,O
76,NUMBER
and,O
11,DURATION
years,DURATION
old,DURATION
.,O
respectively,O
.,O
The,O
range,O
of,O
age,O
of,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
was,O
dominantly,O
30,NUMBER
‐,O
49,DURATION
years,DURATION
old,DURATION
[,O
25,NUMBER
(,O
52.1,PERCENT
%,PERCENT
),O
of,O
48,NUMBER
],O
.,O
fol,O
‐,O
lowed,O
by,O
those,O
aged,O
over,O
60,DURATION
years,DURATION
old,DURATION
[,O
11,NUMBER
(,O
22.9,PERCENT
%,PERCENT
),O
of,O
48,NUMBER
],O
.,O
There,O
were,O
no,O
children,O
who,O
were,O
aged,O
under,O
10,DURATION
years,DURATION
old,DURATION
.,O
Besides,O
.,O
29.2,PERCENT
%,PERCENT
(,O
14,NUMBER
of,O
48,NUMBER
),O
of,O
patients,O
had,O
basic,O
diseases,CAUSE_OF_DEATH
.,O
and,O
57.2,PERCENT
%,PERCENT
(,O
8,NUMBER
of,O
14,NUMBER
),O
of,O
patients,O
with,O
basic,O
diseases,CAUSE_OF_DEATH
were,O
aged,O
over,O
60,DURATION
years,DURATION
old,DURATION
.,O
The,O
prevalence,O
of,O
COVID,O
‐,O
19,NUMBER
in,O
patients,O
over,O
60,DURATION
years,DURATION
old,DURATION
with,O
basic,O
diseases,CAUSE_OF_DEATH
was,O
significantly,O
higher,O
than,O
that,O
in,O
patients,O
without,O
basic,O
It,O
was,O
unveiled,O
that,O
there,O
were,O
31,NUMBER
(,O
64.6,PERCENT
%,PERCENT
),O
male,O
patients,O
and,O
17,NUMBER
(,O
35.4,PERCENT
%,PERCENT
),O
female,O
patients,O
.,O
with,O
a,O
female,O
‐,O
to,O
‐,O
male,O
ratio,O
of,O
1.82:1,NUMBER
.,O
The,O
occupations,O
of,O
48,NUMBER
COVID,O
‐,O
19,NUMBER
patients,O
were,O
mainly,O
farm,O
‐,O
ers,O
working,O
in,O
agricultural,O
production,O
[,O
15,NUMBER
(,O
31.5,PERCENT
%,PERCENT
),O
of,O
48,NUMBER
],O
.,O
rural,O
migrant,O
workers,O
from,O
Hengyang,CITY
to,O
Wuhan,CITY
[,O
15,NUMBER
(,O
31.5,PERCENT
%,PERCENT
),O
],O
.,O
and,O
service,O
workers,O
operating,O
in,O
the,O
service,O
sector,O
[,O
8,NUMBER
(,O
16.7,PERCENT
%,PERCENT
),O
],O
.,O
The,O
patients,O
demographic,O
characteristics,O
Epidemiological,O
history,O
Among,O
48,NUMBER
COVID,O
‐,O
19,NUMBER
patients,O
.,O
there,O
was,O
no,O
history,O
of,O
wildlife,O
exposure,O
(,O
in,O
‐,O
cluding,O
direct,O
contact,O
with,O
animals,O
and,O
visits,O
to,O
the,O
wildlife,O
market,O
),O
within,O
14,NUMBER
d,O
.,O
and,O
58.3,PERCENT
%,PERCENT
Zhong,O
ZF,O
et,O
al,O
.,O
Epidemiological,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
T,O
(,O
n,O
=,O
48,NUMBER
),O
A,O
(,O
n,O
=,O
31,NUMBER
),O
B,O
(,O
n,O
=,O
17,NUMBER
),O
2,NUMBER
(,O
P,O
value1,O
),O
C,O
(,O
n,O
=,O
14,NUMBER
),O
D,O
(,O
n,O
=,O
34,NUMBER
),O
2,NUMBER
(,O
P,O
value2,O
),O
E,O
(,O
n,O
=,O
38,NUMBER
),O
F,O
(,O
n,O
=,O
9,NUMBER
),O
2,NUMBER
(,O
P,O
value3,O
),O
Age,O
(,O
years,DURATION
old,O
),O
Office,O
staff,O
Service,O
workers,O
Rural,O
migrant,O
Indicates,O
differences,O
between,O
male,O
and,O
fe,O
‐,O
male,O
patients,O
.,O
Denotes,O
differences,O
between,O
patients,O
with,O
and,O
without,O
basic,O
diseases,CAUSE_OF_DEATH
.,O
Represents,O
differences,O
between,O
moderate,O
and,O
severe,O
patients,O
.,O
P,O
<,O
0.05,NUMBER
was,O
considered,O
statistically,O
sig,O
‐,O
nificant,O
.,O
T,O
:,O
All,O
patients,O
;,O
A,O
:,O
Male,O
;,O
B,O
:,O
Female,O
;,O
C,O
:,O
With,O
basic,O
dis,O
‐,O
eases,O
;,O
D,O
:,O
Without,O
basic,O
diseases,CAUSE_OF_DEATH
;,O
E,O
:,O
Moderate,O
;,O
F,O
:,O
Severe,O
.,O
(,O
28,NUMBER
of,O
48,NUMBER
),O
had,O
a,O
history,O
of,O
travel,O
to,O
or,O
residency,O
in,O
Wuhan,CITY
and,O
sur,O
‐,O
rounding,O
areas,O
.,O
In,O
addition,O
.,O
31.3,PERCENT
%,PERCENT
(,O
15,NUMBER
of,O
48,NUMBER
),O
had,O
a,O
history,O
of,O
contact,O
with,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
within,O
14,NUMBER
d,O
;,O
10.4,PERCENT
%,PERCENT
(,O
5,NUMBER
of,O
48,NUMBER
),O
had,O
a,O
history,O
of,O
contact,O
with,O
patients,O
with,O
fever,CAUSE_OF_DEATH
or,O
respiratory,O
symptoms,O
from,O
the,O
epidemic,O
area,O
within,O
14,NUMBER
d,O
prior,O
to,O
onset,O
;,O
22.9,PERCENT
%,PERCENT
(,O
11,NUMBER
of,O
48,NUMBER
),O
had,O
clustered,O
onset,O
.,O
which,O
occurred,O
in,O
10,NUMBER
families,O
and,O
1,NUMBER
community,O
;,O
8.3,PERCENT
%,PERCENT
(,O
4,NUMBER
of,O
48,NUMBER
),O
of,O
patients,O
had,O
an,O
unclear,O
epidemic,O
history,O
.,O
Date,O
distribution,O
of,O
confirmed,O
cases,O
distribution,O
of,O
confirmed,O
cases,O
of,O
COVID,O
‐,O
19,NUMBER
by,O
date,O
of,O
onset,O
.,O
It,O
was,O
uncovered,O
that,O
there,O
were,O
no,O
new,O
confirmed,O
cases,O
in,O
Hengyang,CITY
after,O
February,DATE
14,NUMBER
.,O
2020,DATE
.,O
Latent,O
period,O
The,O
latent,O
period,O
was,O
defined,O
as,O
the,O
time,O
from,O
exposure,O
to,O
the,O
onset,O
of,O
symptoms,O
.,O
which,O
was,O
estimated,O
among,O
patients,O
who,O
could,O
provide,O
the,O
exact,O
date,O
of,O
close,O
contact,O
with,O
individuals,O
from,O
Wuhan,CITY
and,O
other,O
epidemic,O
areas,O
with,O
con,O
‐,O
firmed,O
or,O
suspected,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
.,O
The,O
longest,O
latent,O
pe,O
‐,O
riod,O
was,O
15,DURATION
days,DURATION
and,O
the,O
shortest,O
was,O
1,DURATION
day,DURATION
.,O
The,O
mean,O
latent,O
pe,O
‐,O
riod,O
was,O
6.86,NUMBER
3.57,NUMBER
d,O
.,O
and,O
the,O
median,O
was,O
7,NUMBER
Mean,O
time,O
of,O
first,ORDINAL
physician,TITLE
visit,O
and,O
confirmed,O
diagnosis,O
The,O
mean,O
time,O
from,O
onset,O
of,O
symptoms,O
to,O
the,O
first,ORDINAL
physician,TITLE
visit,O
was,O
3.38,NUMBER
2.98,NUMBER
(,O
95,PERCENT
%,PERCENT
CI,O
:,O
2.58,NUMBER
‐,O
9.18,NUMBER
),O
d,O
.,O
with,O
a,O
median,O
of,O
2,NUMBER
(,O
IQR,O
:,O
1,NUMBER
‐,O
5,NUMBER
),O
d,O
.,O
and,O
the,O
mean,O
time,O
from,O
hospital,O
admission,O
to,O
confirmed,O
diagnosis,O
was,O
2.29,NUMBER
2.11,NUMBER
(,O
95,PERCENT
%,PERCENT
CI,O
:,O
1.18,NUMBER
‐,O
6.42,NUMBER
),O
d,O
.,O
with,O
a,O
median,O
of,O
2,NUMBER
(,O
IQR,O
:,O
1,NUMBER
‐,O
3,NUMBER
),O
d.,O
Basic,O
diseases,CAUSE_OF_DEATH
It,O
was,O
uncovered,O
that,O
29.2,PERCENT
%,PERCENT
(,O
14,NUMBER
of,O
48,NUMBER
),O
of,O
patients,O
had,O
basic,O
diseases,CAUSE_OF_DEATH
(,O
also,O
known,O
as,O
Co,O
‐,O
morbidities,O
),O
.,O
including,O
2,NUMBER
cases,O
of,O
coronary,O
disease,CAUSE_OF_DEATH
.,O
1,NUMBER
case,O
of,O
hypertension,CAUSE_OF_DEATH
.,O
1,NUMBER
case,O
of,O
coronary,O
disease,CAUSE_OF_DEATH
with,O
hypertension,CAUSE_OF_DEATH
.,O
diabetes,CAUSE_OF_DEATH
.,O
and,O
cerebral,O
infarction,O
.,O
2,NUMBER
cases,O
of,O
diabetes,CAUSE_OF_DEATH
with,O
hypertension,CAUSE_OF_DEATH
and,O
hyperlipidemia,O
.,O
1,NUMBER
case,O
of,O
diabetes,CAUSE_OF_DEATH
with,O
hypertension,CAUSE_OF_DEATH
and,O
gout,O
.,O
and,O
7,NUMBER
cases,O
of,O
chronic,O
hep,O
‐,O
atitis,O
B,O
.,O
In,O
the,O
7,NUMBER
cases,O
of,O
chronic,O
hepatitis,CAUSE_OF_DEATH
B,CAUSE_OF_DEATH
.,O
the,O
serum,O
mark,O
‐,O
ers,O
of,O
hepatitis,CAUSE_OF_DEATH
B,CAUSE_OF_DEATH
were,O
positive,O
for,O
hepatitis,CAUSE_OF_DEATH
B,CAUSE_OF_DEATH
surface,O
antigen,O
.,O
hepatitis,CAUSE_OF_DEATH
B,CAUSE_OF_DEATH
e,O
antibody,O
.,O
and,O
hepatitis,CAUSE_OF_DEATH
B,CAUSE_OF_DEATH
c,O
antibody,O
.,O
6,NUMBER
cases,O
had,O
HBV,O
‐,O
DNA,O
titers,O
<,O
500,NUMBER
IU,O
/,O
mL,O
.,O
and,O
1,NUMBER
case,O
had,O
an,O
HBV,O
‐,O
DNA,O
titer,O
>,O
500,NUMBER
IU,O
/,O
mL,O
.,O
Except,O
for,O
1,NUMBER
case,O
with,O
elevated,O
Zhong,O
ZF,O
et,O
al,O
.,O
Epidemio,O
‐,O
logical,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
alanine,O
amino,O
‐,O
transferase,O
(,O
ALT,O
),O
and,O
1,NUMBER
case,O
with,O
elevated,O
aspartate,O
aminotrans,O
‐,O
ferase,O
(,O
AST,O
),O
.,O
the,O
remaining,O
5,NUMBER
patients,O
had,O
normal,O
liver,O
function,O
.,O
and,O
7,NUMBER
patients,O
did,O
not,O
take,O
antiviral,O
drugs,CRIMINAL_CHARGE
.,O
Symptoms,O
and,O
signs,O
The,O
most,O
common,O
symptoms,O
at,O
the,O
time,DATE
of,O
admission,O
were,O
fever,CAUSE_OF_DEATH
[,O
43,NUMBER
(,O
89.6,PERCENT
%,PERCENT
),O
of,O
48,NUMBER
],O
.,O
cough,O
and,O
expectoration,O
[,O
41,NUMBER
(,O
85.4,PERCENT
%,PERCENT
),O
],O
.,O
chills,O
[,O
22,NUMBER
(,O
45.8,PERCENT
%,PERCENT
),O
],O
.,O
and,O
fatigue,O
[,O
22,NUMBER
(,O
45.8,PERCENT
%,PERCENT
),O
],O
.,O
Other,O
symptoms,O
included,O
poor,O
appetite,O
[,O
13,NUMBER
(,O
27.1,PERCENT
%,PERCENT
),O
],O
.,O
sore,O
throat,O
[,O
9,NUMBER
(,O
18.8,PERCENT
%,PERCENT
),O
],O
.,O
dyspnea,O
[,O
9,NUMBER
(,O
18.8,PERCENT
%,PERCENT
),O
],O
.,O
diarrhea,O
[,O
7,NUMBER
(,O
14.6,PERCENT
%,PERCENT
),O
],O
.,O
dizziness,O
[,O
5,NUMBER
(,O
10.4,PERCENT
%,PERCENT
),O
],O
.,O
headache,O
[,O
5,NUMBER
(,O
10.4,PERCENT
%,PERCENT
),O
],O
.,O
muscle,O
pain,O
[,O
5,NUMBER
(,O
10.4,PERCENT
%,PERCENT
),O
],O
.,O
nausea,O
and,O
vomiting,O
[,O
4,NUMBER
(,O
8.3,PERCENT
%,PERCENT
),O
],O
.,O
hemoptysis,O
[,O
4,NUMBER
(,O
8.3,PERCENT
%,PERCENT
),O
],O
.,O
and,O
runny,O
nose,O
[,O
1,NUMBER
(,O
2.1,PERCENT
%,PERCENT
),O
],O
.,O
At,O
the,O
time,O
of,O
admission,O
.,O
the,O
mean,O
body,O
temperature,O
was,O
38.3,NUMBER
0.8,NUMBER
C,O
.,O
and,O
respiratory,O
frequency,O
was,O
21.17,NUMBER
1.78,NUMBER
times,O
/,O
min,DURATION
.,O
The,O
clinical,O
symptoms,O
are,O
Laboratory,O
results,O
In,O
the,O
first,ORDINAL
blood,O
routine,O
exami,O
‐,O
nation,O
.,O
the,O
majority,O
[,O
29,NUMBER
(,O
60.4,PERCENT
%,PERCENT
),O
of,O
48,NUMBER
],O
of,O
patients,O
were,O
in,O
nor,O
‐,O
mal,O
range,O
.,O
and,O
the,O
levels,O
of,O
leucocytes,O
were,O
reduced,O
in,O
about,O
one,NUMBER
third,ORDINAL
of,O
patients,O
[,O
18,NUMBER
(,O
37.5,PERCENT
%,PERCENT
),O
],O
.,O
Neutrophil,O
count,TITLE
was,O
in,O
normal,O
range,O
in,O
the,O
majority,O
of,O
patients,O
[,O
38,NUMBER
(,O
79.2,PERCENT
%,PERCENT
),O
],O
.,O
and,O
it,O
was,O
de,O
‐,O
creased,O
in,O
some,O
[,O
7,NUMBER
(,O
14.6,PERCENT
%,PERCENT
),O
],O
and,O
increased,O
in,O
a,O
limited,O
number,O
of,O
patients,O
[,O
3,NUMBER
(,O
6.2,PERCENT
%,PERCENT
),O
],O
.,O
The,O
lymphocyte,O
count,TITLE
was,O
reduced,O
in,O
the,O
ma,O
‐,O
jority,O
of,O
patients,O
[,O
34,NUMBER
(,O
70.8,PERCENT
%,PERCENT
),O
of,O
48,NUMBER
],O
.,O
was,O
in,O
normal,O
range,O
in,O
about,O
one,NUMBER
third,ORDINAL
of,O
patients,O
[,O
13,NUMBER
(,O
27.1,PERCENT
%,PERCENT
),O
],O
.,O
and,O
was,O
elevated,O
in,O
a,O
small,O
number,O
of,O
cases,O
[,O
1,NUMBER
(,O
2.1,PERCENT
%,PERCENT
),O
],O
.,O
The,O
eosinophil,O
count,TITLE
was,O
sig,O
‐,O
nificantly,O
reduced,O
[,O
48,NUMBER
(,O
100.0,PERCENT
%,PERCENT
),O
],O
.,O
The,O
liver,O
function,O
tests,O
showed,O
that,O
serum,O
levels,O
of,O
ALT,O
.,O
AST,ORGANIZATION
.,O
‐,O
GT,O
.,O
and,O
alkaline,O
phos,O
‐,O
phatase,O
were,O
increased,O
in,O
22.9,PERCENT
%,PERCENT
(,O
11,NUMBER
of,O
48,NUMBER
),O
.,O
20.8,PERCENT
%,PERCENT
(,O
10,NUMBER
of,O
48,NUMBER
),O
.,O
21.6,PERCENT
%,PERCENT
(,O
8,NUMBER
of,O
37,NUMBER
),O
.,O
and,O
5.4,PERCENT
%,PERCENT
(,O
2,NUMBER
of,O
37,NUMBER
),O
of,O
patients,O
.,O
respectively,O
.,O
The,O
abnormal,O
incidence,O
of,O
ALT,O
elevation,O
in,O
male,O
patients,O
was,O
sig,O
‐,O
nificantly,O
higher,O
than,O
that,O
in,O
female,O
patients,O
(,O
P,O
<,O
0.01,NUMBER
),O
.,O
while,O
the,O
abnormal,O
incidence,O
of,O
AST,ORGANIZATION
elevation,O
in,O
severe,O
patients,O
was,O
significantly,O
increased,O
compared,O
with,O
moderate,O
patients,O
(,O
P,O
<,O
0.05,NUMBER
),O
.,O
After,O
patients,O
with,O
liver,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
were,O
excluded,O
.,O
there,O
were,O
17.07,PERCENT
%,PERCENT
(,O
7,NUMBER
of,O
41,NUMBER
),O
of,O
patients,O
with,O
elevated,O
levels,O
of,O
ALT,O
and,O
AST,ORGANIZATION
.,O
and,O
24.24,PERCENT
%,PERCENT
(,O
8,NUMBER
of,O
33,NUMBER
),O
with,O
elevated,O
level,O
of,O
‐,O
GT,O
.,O
The,O
serum,O
myocardial,O
enzyme,O
test,O
revealed,O
that,O
the,O
levels,O
of,O
lactate,O
dehy,O
‐,O
drogenase,O
(,O
LD,O
‐,O
L,O
),O
.,O
myoglobin,O
(,O
MB,STATE_OR_PROVINCE
),O
.,O
and,O
creatine,O
kinase,O
(,O
CK,O
),O
were,O
increased,O
in,O
37.0,PERCENT
%,PERCENT
(,O
17,NUMBER
of,O
46,NUMBER
),O
.,O
13.6,PERCENT
%,PERCENT
(,O
6,NUMBER
of,O
44,NUMBER
),O
.,O
and,O
12.8,PERCENT
%,PERCENT
(,O
6,NUMBER
of,O
47,NUMBER
),O
of,O
patients,O
.,O
respectively,O
.,O
The,O
incidence,O
of,O
abnormal,O
CK,O
ele,O
‐,O
vation,O
in,O
severe,O
patients,O
was,O
significantly,O
higher,O
than,O
that,O
in,O
moderate,O
patients,O
(,O
P,O
<,O
0.05,NUMBER
),O
.,O
For,O
renal,O
function,O
test,O
.,O
some,O
pa,O
‐,O
tients,O
[,O
10,NUMBER
(,O
20.9,PERCENT
%,PERCENT
),O
of,O
48,NUMBER
],O
were,O
found,O
to,O
have,O
increased,O
levels,O
of,O
uric,O
acid,O
.,O
In,O
terms,O
of,O
fibrinolysis,O
detection,O
.,O
the,O
levels,O
of,O
fib,O
‐,O
rinogen,O
and,O
D,O
‐,O
dimer,O
were,O
increased,O
in,O
44.7,PERCENT
%,PERCENT
(,O
21,NUMBER
of,O
47,NUMBER
),O
and,O
29.5,PERCENT
%,PERCENT
(,O
13,NUMBER
of,O
44,NUMBER
),O
of,O
patients,O
.,O
respectively,O
.,O
Additionally,O
.,O
elevated,O
serum,O
levels,O
of,O
C,O
‐,O
reactive,O
protein,O
and,O
blood,O
glucose,O
were,O
noted,O
in,O
64.6,PERCENT
%,PERCENT
(,O
31,NUMBER
of,O
48,NUMBER
),O
and,O
43.2,PERCENT
%,PERCENT
(,O
19,NUMBER
of,O
48,NUMBER
),O
of,O
patients,O
.,O
respective,O
‐,O
ly,O
.,O
Compared,O
with,O
moderate,O
patients,O
.,O
the,O
incidence,O
of,O
abnormal,O
levels,O
of,O
blood,O
glucose,O
was,O
remarkably,O
increased,O
in,O
the,O
severe,O
patients,O
(,O
P,O
<,O
0.05,NUMBER
),O
.,O
The,O
results,O
Chest,O
computed,O
tomography,O
Except,O
for,O
1,NUMBER
mild,O
case,O
.,O
other,O
patients,O
[,O
47,NUMBER
(,O
97.92,PERCENT
%,PERCENT
),O
of,O
48,NUMBER
],O
had,O
pulmonary,O
lesions,O
.,O
of,O
Zhong,PERSON
ZF,O
et,O
al,O
.,O
Epidemiological,O
and,O
clinical,O
charac,O
‐,O
teristics,O
of,O
COVID,O
‐,O
19,NUMBER
T,O
(,O
n,O
=,O
48,NUMBER
),O
A,O
(,O
n,O
=,O
31,NUMBER
),O
B,O
(,O
n,O
=,O
17,NUMBER
),O
2,NUMBER
(,O
P,O
val,O
‐,O
ue1,O
),O
C,O
(,O
n,O
=,O
14,NUMBER
),O
D,O
(,O
n,O
=,O
34,NUMBER
),O
2,NUMBER
(,O
P,O
value2,O
),O
E,O
(,O
n,O
=,O
38,NUMBER
),O
F,O
(,O
n,O
=,O
9,NUMBER
),O
2,NUMBER
(,O
P,O
value3,O
),O
Cough,O
and,O
Poor,O
appetite,O
Sore,O
throat,O
Muscle,O
ache,O
Nausea,O
and,O
vomiting,O
Runny,O
nose,O
Indicates,O
differences,O
between,O
male,O
and,O
female,O
patients,O
.,O
Denotes,O
differences,O
between,O
patients,O
with,O
and,O
without,O
basic,O
diseases,CAUSE_OF_DEATH
.,O
Represents,O
differences,O
between,O
moderate,O
and,O
severe,O
patients,O
.,O
P,O
<,O
0.05,NUMBER
was,O
considered,O
statistically,O
sig,O
‐,O
nificant,O
.,O
T,O
:,O
All,O
patients,O
;,O
A,O
:,O
Male,O
;,O
B,O
:,O
Female,O
;,O
C,O
:,O
With,O
basic,O
dis,O
‐,O
eases,O
;,O
D,O
:,O
Without,O
basic,O
diseases,CAUSE_OF_DEATH
;,O
E,O
:,O
Moderate,O
;,O
F,O
:,O
Severe,O
.,O
which,O
8.33,PERCENT
%,PERCENT
(,O
4,NUMBER
of,O
48,NUMBER
),O
were,O
single,O
lung,O
lesions,O
and,O
89.58,PERCENT
%,PERCENT
(,O
43,NUMBER
of,O
48,NUMBER
),O
were,O
double,O
lung,O
lesions,O
.,O
Pleural,O
effusion,O
appeared,O
in,O
2,NUMBER
[,O
2,NUMBER
(,O
4.17,PERCENT
%,PERCENT
),O
],O
cases,O
as,O
well,O
.,O
Average,O
time,O
from,O
onset,O
to,O
the,O
first,ORDINAL
ap,O
‐,O
pearance,O
of,O
lung,O
lesions,O
in,O
chest,O
computed,O
tomography,O
(,O
CT,STATE_OR_PROVINCE
),O
was,O
3.18,NUMBER
2.71,NUMBER
(,O
95,PERCENT
%,PERCENT
CI,O
:,O
3.031,NUMBER
‐,O
4.63,NUMBER
),O
d.,O
Multiple,O
small,O
patchy,O
shadows,O
and,O
interstitial,O
changes,O
in,O
the,O
early,O
stage,O
of,O
lung,O
lesions,O
were,O
evident,O
in,O
the,O
extra,O
‐,O
pulmonary,O
zone,O
;,O
as,O
the,O
disease,CAUSE_OF_DEATH
progresses,O
.,O
multiple,O
ground,O
glass,O
shadows,O
and,O
invasive,O
lesions,O
may,O
illus,O
‐,O
trates,O
dynamic,O
changes,O
of,O
chest,O
CT,STATE_OR_PROVINCE
in,O
1,NUMBER
case,O
of,O
severe,O
COVID,O
‐,O
19,NUMBER
.,O
Treatment,O
effect,O
All,O
the,O
patients,O
received,O
antiviral,O
drugs,CRIMINAL_CHARGE
.,O
in,O
‐,O
cluding,O
alpha,O
‐,O
interferon,O
(,O
5,NUMBER
million,NUMBER
units,O
.,O
atomization,O
;,O
average,O
.,O
11.2,NUMBER
d,O
),O
.,O
lopinavir,O
/,O
ritonavir,O
(,O
500,NUMBER
mg,O
BID,O
;,O
average,O
.,O
9.9,NUMBER
d,O
),O
.,O
ar,O
‐,O
bidol,O
(,O
200,NUMBER
mg,O
TID,O
;,O
average,O
.,O
7.8,NUMBER
d,O
),O
.,O
and,O
chloroquine,O
phosphate,O
(,O
500,NUMBER
mg,O
BID,O
;,O
average,O
.,O
7.0,NUMBER
d,O
),O
.,O
Moreover,O
.,O
38,NUMBER
(,O
79.2,PERCENT
%,PERCENT
),O
patients,O
were,O
given,O
TCM,ORGANIZATION
based,O
on,O
the,O
treatment,O
protocol,O
[,O
7,NUMBER
],O
.,O
Furthermore,O
.,O
2,NUMBER
(,O
4.2,PERCENT
%,PERCENT
),O
patients,O
received,O
treatment,O
of,O
human,O
umbilical,O
‐,O
cord,O
mes,O
‐,O
enchymal,O
stem,O
cells,O
.,O
A,O
number,O
of,O
patients,O
.,O
mainly,O
those,O
with,O
co,O
‐,O
infection,CAUSE_OF_DEATH
.,O
were,O
treated,O
with,O
antibiotics,O
including,O
moxifloxacin,O
.,O
cefoperazone,O
sodium,O
.,O
and,O
sulbactam,O
sodium,O
.,O
Severe,O
patients,O
were,O
given,O
methylprednisolone,O
(,O
1,NUMBER
‐,O
2,NUMBER
mg,O
/,O
kg,O
per,O
day,DURATION
),O
and,O
immunoglobulin,O
for,O
3,NUMBER
‐,O
5,NUMBER
d.,O
On,O
March,DATE
2,DATE
.,DATE
2020,DATE
.,O
all,O
the,O
48,NUMBER
patients,O
with,O
confirmed,O
COVID,O
‐,O
19,NUMBER
were,O
cured,O
and,O
discharged,O
.,O
Analysis,O
of,O
epidemiological,O
characteristics,O
The,O
outbreak,O
of,O
COVID,O
‐,O
19,NUMBER
in,O
China,COUNTRY
is,O
roughly,O
di,O
‐,O
vided,O
into,O
three,NUMBER
phases,O
[,O
9.10,NUMBER
],O
.,O
The,O
first,ORDINAL
phase,O
occurred,O
before,O
the,DATE
end,DATE
of,DATE
December,DATE
2019,DATE
.,O
COVID,O
‐,O
19,NUMBER
mainly,O
caused,O
a,O
local,O
outbreak,O
among,O
people,O
who,O
had,O
contact,O
with,O
seafood,O
markets,O
.,O
In,O
early,O
Janu,PERSON
‐,PERSON
ary,O
2020,DATE
.,DATE
the,DATE
second,DATE
phase,O
commenced,O
.,O
with,O
clusters,O
of,O
disease,CAUSE_OF_DEATH
in,O
multiple,O
communities,O
or,O
families,O
in,O
Wuhan,CITY
and,O
human,O
‐,O
to,O
‐,O
human,O
transmission,O
among,O
close,O
contacts,O
[,O
10.11,NUMBER
],O
.,O
In,O
mid,O
‐,O
to,O
‐,O
late,DATE
January,DATE
2020,DATE
.,O
with,O
the,O
approach,O
of,O
the,O
Spring,DATE
Festival,O
.,O
personnel,O
mobili,O
‐,O
ty,O
increased,O
.,O
and,O
the,O
third,ORDINAL
phase,O
of,O
outbreak,O
appeared,O
.,O
At,O
this,O
time,O
.,O
the,O
epidemic,O
spread,O
from,O
Hubei,STATE_OR_PROVINCE
Province,LOCATION
to,O
other,O
provinces,O
in,O
mainland,O
China,COUNTRY
[,O
10,NUMBER
],O
.,O
Hengyang,CITY
(,O
Hunan,STATE_OR_PROVINCE
Province,LOCATION
),O
.,O
a,O
close,O
neigh,O
‐,O
bor,O
of,O
Hubei,STATE_OR_PROVINCE
Province,LOCATION
.,O
began,O
to,O
have,O
an,O
outbreak,O
in,O
mid,O
‐,O
January,DATE
2020,DATE
.,O
just,O
before,O
commencing,O
the,O
traditional,O
Chinese,NATIONALITY
New,DATE
Year,DATE
.,O
The,O
first,ORDINAL
case,O
of,O
COVID,O
‐,O
19,NUMBER
onset,O
was,O
found,O
on,O
January,DATE
16,DATE
.,DATE
2020,DATE
.,O
and,O
the,O
onset,O
occurred,O
2,NUMBER
d,O
after,O
he,O
contacted,O
with,O
people,O
from,O
Wuhan,CITY
.,O
The,O
distribution,O
of,O
confirmed,O
cases,O
of,O
COVID,O
‐,O
19,NUMBER
by,O
date,O
of,O
onset,O
in,O
Hengyang,CITY
was,O
mainly,O
concentrated,O
from,O
mid,O
‐,O
January,DATE
to,O
late,O
‐,O
January,DATE
.,O
No,O
new,O
cases,O
were,O
found,O
in,O
Hengyang,CITY
after,O
Zhong,PERSON
ZF,PERSON
et,O
al,O
.,O
Epidemiological,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
Urea,O
nitrogen,O
(,O
mmol,O
/,O
L,O
),O
n,O
=,O
48,NUMBER
Uric,O
acid,O
(,O
mol,O
/,O
L,O
),O
Routine,O
blood,O
pa,O
‐,O
rameter,O
Liver,O
function,O
Renal,MISC
function,O
Zhong,PERSON
ZF,O
et,O
al,O
.,O
Epidemio,O
‐,O
logical,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
Creatine,O
kinase,O
(,O
U,O
/,O
L,O
),O
C,O
‐,O
reactive,O
protein,O
Blood,O
glucose,O
(,O
mmol,O
/,O
L,O
),O
n,O
=,O
48,NUMBER
Myocardial,O
enzymes,O
Indicates,O
differences,O
between,O
male,O
and,O
female,O
patients,O
.,O
Denotes,O
differences,O
between,O
patients,O
with,O
and,O
without,O
basic,O
dis,O
‐,O
eases,O
.,O
Represents,O
differences,O
between,O
moderate,O
and,O
severe,O
pa,O
‐,O
tients,O
.,O
P,O
<,O
0.05,NUMBER
was,O
considered,O
statistically,O
significant,O
.,O
T,O
:,O
All,O
patients,O
;,O
A,O
:,O
Male,O
;,O
B,O
:,O
Female,O
;,O
C,O
:,O
With,O
basic,O
diseases,CAUSE_OF_DEATH
;,O
D,O
:,O
Without,O
basic,O
diseases,CAUSE_OF_DEATH
;,O
E,O
:,O
Moderate,O
;,O
F,O
:,O
Severe,O
.,O
ALT,O
:,O
Alanine,O
aminotrans,O
‐,O
ferase,O
;,O
AST,O
:,O
Aspartate,O
aminotransferase,O
;,O
LD,O
‐,O
L,O
:,O
Lactate,O
dehydroge,O
‐,O
nase,O
;,O
ALP,O
:,O
Alkaline,O
phosphatase,O
;,O
‐,O
GT,O
:,O
‐,O
glutamyl,O
transpeptidase,O
.,O
February,DATE
14,DATE
.,O
due,O
to,O
non,O
‐,O
pharmacological,O
interventions,O
adopted,O
in,O
China,COUNTRY
.,O
including,O
wearing,O
masks,O
and,O
home,O
isolation,O
.,O
which,O
effec,O
‐,O
tively,O
cut,O
off,O
the,O
transmission,O
route,O
of,O
the,O
virus,O
.,O
None,O
of,O
the,O
patients,O
in,O
Hengyang,CITY
had,O
a,O
history,O
of,O
wild,O
animal,O
contact,O
within,O
14,NUMBER
d,O
.,O
excluding,O
the,O
possibility,O
of,O
animal,O
infection,CAUSE_OF_DEATH
.,O
Approximate,O
‐,O
ly,O
58.3,PERCENT
%,PERCENT
of,O
the,O
patients,O
had,O
a,O
history,O
of,O
travel,O
or,O
residency,O
in,O
the,O
epidemic,O
areas,O
of,O
Wuhan,ORGANIZATION
14,NUMBER
d,O
before,O
onset,O
.,O
indicating,O
that,O
the,O
early,O
cases,O
of,O
Hengyang,CITY
were,O
introduced,O
from,O
Wuhan,CITY
;,O
31.3,PERCENT
%,PERCENT
had,O
no,O
contact,O
with,O
the,O
epidemic,O
areas,O
within,O
14,NUMBER
d,O
.,O
while,O
there,O
was,O
a,O
clear,O
history,O
of,O
contact,O
with,O
the,O
patients,O
infected,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
Besides,O
.,O
22.9,PERCENT
%,PERCENT
had,O
clustered,O
onset,O
.,O
of,O
which,O
10,NUMBER
were,O
in,O
family,O
and,O
1,NUMBER
in,O
community,O
.,O
The,O
characteristics,O
of,O
the,O
clustered,O
onset,O
are,O
similar,O
to,O
those,O
of,O
other,O
regions,O
in,O
China,COUNTRY
[,O
9.10,NUMBER
],O
.,O
Among,O
the,O
48,NUMBER
COVID,O
‐,O
19,NUMBER
patients,O
.,O
the,O
mean,O
time,O
from,O
onset,O
of,O
symp,O
‐,O
toms,O
to,O
the,O
first,ORDINAL
physician,TITLE
visit,O
was,O
3.78,NUMBER
2.98,NUMBER
d,O
.,O
and,O
the,O
mean,O
time,O
from,O
hospital,O
admission,O
to,O
confirmed,O
diagnosis,O
was,O
2.29,NUMBER
2.11,NUMBER
d,O
.,O
which,O
was,O
shorter,O
than,O
the,O
time,O
reported,O
in,O
the,O
litera,O
‐,O
ture,O
[,O
9.10,NUMBER
],O
.,O
These,O
are,O
closely,O
related,O
to,O
the,O
government,O
and,O
resi,O
‐,O
dents,O
attaching,O
great,O
importance,O
to,O
the,O
prevention,O
and,O
treatment,O
of,O
COVID,O
‐,O
19,NUMBER
and,O
technological,O
advancements,O
in,O
health,O
care,O
.,O
Anal,O
‐,O
ysis,O
of,O
clinical,O
characteristics,O
Totally,O
.,O
48,NUMBER
patients,O
with,O
COVID,O
‐,O
19,NUMBER
were,O
enrolled,O
.,O
of,O
which,O
1,NUMBER
was,O
mild,O
.,O
38,NUMBER
were,O
moderate,O
.,O
and,O
9,NUMBER
were,O
severe,O
.,O
Compared,O
with,O
patients,O
who,O
were,O
initially,O
in,O
‐,O
fected,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
Wuhan,CITY
[,O
11,NUMBER
],O
.,O
the,O
severity,O
of,O
illness,CAUSE_OF_DEATH
of,O
patients,O
in,O
Hengyang,CITY
was,O
relatively,O
mild,O
.,O
The,O
common,O
symptoms,O
of,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
in,O
Hengyang,CITY
were,O
fever,CAUSE_OF_DEATH
.,O
cough,O
.,O
fatigue,O
.,O
and,O
chills,O
.,O
Approximately,O
10.4,PERCENT
%,PERCENT
of,O
patients,O
did,O
not,O
have,O
fever,CAUSE_OF_DEATH
and,O
were,O
easily,O
ignored,O
in,O
the,O
daily,SET
temperature,O
screening,O
.,O
Symp,O
‐,O
toms,O
of,O
the,O
upper,O
respiratory,O
tract,O
were,O
rare,O
.,O
with,O
only,O
1,NUMBER
case,O
of,O
runny,O
nose,O
.,O
which,O
was,O
favorable,O
for,O
distinguishing,O
the,O
disease,CAUSE_OF_DEATH
from,O
the,O
upper,O
respiratory,O
tract,O
.,O
One,NUMBER
patient,O
had,O
no,O
symptoms,O
.,O
positive,O
signs,O
.,O
or,O
changes,O
in,O
chest,O
CT,STATE_OR_PROVINCE
before,O
and,O
after,O
hospital,O
‐,O
ization,O
.,O
and,O
only,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
nucleic,O
acid,O
test,O
was,O
positive,O
.,O
which,O
was,O
called,O
asymptomatic,O
novel,O
coronavirus,O
infection,CAUSE_OF_DEATH
.,O
The,O
literature,O
has,O
reported,O
that,O
asymptomatic,O
patients,O
with,O
novel,O
coronavirus,O
infection,CAUSE_OF_DEATH
are,O
also,O
highly,O
infectious,O
[,O
6,NUMBER
],O
.,O
Wong,PERSON
et,O
al,O
[,O
12,NUMBER
],O
found,O
that,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
can,O
be,O
prevented,O
through,O
basic,O
in,O
‐,O
fection,O
control,O
measures,O
.,O
including,O
wearing,O
of,O
masks,O
.,O
washing,O
hands,O
.,O
and,O
environmental,O
hygiene,O
.,O
Zhong,PERSON
ZF,O
et,O
al,O
.,O
Epidemiologi,O
‐,O
cal,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
could,O
be,O
observed,O
in,O
the,O
lower,O
lobe,O
of,O
the,O
right,O
middle,O
lobe,O
and,O
left,O
upper,O
lobe,O
.,O
and,O
consolidation,O
was,O
observed,O
in,O
the,O
lower,O
lobe,O
of,O
both,O
lungs,O
.,O
as,O
well,O
as,O
consolidation,O
of,O
the,O
right,O
lung,O
;,O
B,O
:,O
On,O
day,DURATION
18,NUMBER
of,O
disease,CAUSE_OF_DEATH
onset,O
.,O
the,O
consolidation,O
of,O
the,O
lower,O
lobe,O
of,O
both,O
lungs,O
was,O
sig,O
‐,O
nificantly,O
reduced,O
.,O
and,O
the,O
structure,O
was,O
distorted,O
.,O
The,O
consoli,O
‐,O
dation,O
of,O
the,O
lobe,O
and,O
ground,O
glass,O
was,O
mixed,O
;,O
C,O
:,O
An,O
obvious,O
re,O
‐,O
duction,O
in,O
consolidation,O
of,O
both,O
lungs,O
and,O
increased,O
ground,O
glass,O
opacities,O
in,O
the,O
lower,O
lobe,O
of,O
the,O
left,O
lung,O
could,O
be,O
observed,O
on,O
day,DURATION
23,NUMBER
of,O
disease,CAUSE_OF_DEATH
onset,O
;,O
D,O
:,O
An,O
obvious,O
absorption,O
and,O
decreased,O
density,O
of,O
bilateral,O
lung,O
lesions,O
.,O
mainly,O
ground,O
glass,O
opacities,O
and,O
fiber,O
strand,O
shadow,O
distribution,O
.,O
as,O
well,O
as,O
bronchiectasis,O
of,O
the,O
lower,O
lobe,O
of,O
both,O
lungs,O
could,O
be,O
observed,O
on,O
day,DURATION
31,NUMBER
of,O
disease,CAUSE_OF_DEATH
onset,O
.,O
The,O
laboratory,O
tests,O
showed,O
the,O
following,O
find,O
‐,O
ings,O
:,O
First,ORDINAL
.,O
the,O
numbers,O
of,O
peripheral,O
blood,O
leukocytes,O
.,O
lympho,O
‐,O
cytes,O
.,O
and,O
eosinophils,O
were,O
significantly,O
reduced,O
.,O
especially,O
the,O
number,O
of,O
eosinophils,O
.,O
which,O
was,O
remarkably,O
decreased,O
in,O
all,O
the,O
patients,O
.,O
Second,ORDINAL
.,O
it,O
was,O
revealed,O
that,O
the,O
levels,O
of,O
ALT,O
.,O
AST,ORGANIZATION
.,O
and,O
‐,O
GT,O
were,O
increased,O
in,O
22.9,PERCENT
%,PERCENT
.,O
20.8,PERCENT
%,PERCENT
.,O
and,O
21.6,PERCENT
%,PERCENT
of,O
patients,O
.,O
respectively,O
.,O
At,O
present,DATE
.,O
it,O
is,O
believed,O
that,O
COVID,O
‐,O
19,NUMBER
patients,O
suffer,O
from,O
dysfunction,O
or,O
injury,O
in,O
multiple,O
organs,O
of,O
the,O
body,O
due,O
to,O
the,O
following,O
three,NUMBER
reasons,O
:,O
First,ORDINAL
.,O
the,O
novel,O
coronavirus,O
directly,O
damages,O
the,O
targeted,O
organ,O
[,O
13,NUMBER
‐,O
15,NUMBER
],O
;,O
second,ORDINAL
.,O
the,O
novel,O
coronavirus,O
induces,O
systemic,O
inflammatory,O
immune,O
response,O
in,O
the,O
human,O
body,O
[,O
5,NUMBER
],O
;,O
third,ORDINAL
.,O
toxic,O
and,O
side,O
effects,O
of,O
some,O
drugs,CRIMINAL_CHARGE
are,O
important,O
during,O
the,O
course,O
of,O
COVID,O
‐,O
19,NUMBER
treatment,O
[,O
16,NUMBER
],O
.,O
However,O
.,O
further,O
research,O
should,O
be,O
conducted,O
to,O
confirm,O
the,O
above,O
‐,O
men,O
‐,O
tioned,O
findings,O
.,O
Except,O
for,O
one,NUMBER
mild,O
patient,O
.,O
the,O
other,O
47,NUMBER
pa,O
‐,O
tients,O
had,O
morphological,O
characteristic,O
of,O
pulmonary,O
lesions,O
on,O
chest,O
CT,STATE_OR_PROVINCE
.,O
which,O
plays,O
a,O
pivotal,O
role,O
in,O
diagnosing,O
COVID19,O
[,O
17,NUMBER
],O
.,O
The,O
pandemic,O
of,O
COVID,O
‐,O
19,NUMBER
caused,O
by,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
presents,O
an,O
un,O
‐,O
precedented,O
challenge,O
to,O
identify,O
effective,O
drugs,CRIMINAL_CHARGE
for,O
prevention,O
and,O
treatment,O
[,O
18,NUMBER
],O
.,O
The,O
patients,O
in,O
the,O
present,DATE
study,O
were,O
treated,O
with,O
a,O
combination,O
of,O
Western,MISC
medicine,O
and,O
TCM,ORGANIZATION
.,O
None,O
of,O
the,O
38,NUMBER
ordinary,O
patients,O
got,O
worse,O
and,O
became,O
severe,O
.,O
and,O
all,O
48,NUMBER
pa,O
‐,O
tients,O
were,O
cured,O
and,O
discharged,O
.,O
In,O
the,O
absence,O
of,O
effective,O
drugs,CRIMINAL_CHARGE
for,O
COVID,O
‐,O
19,NUMBER
[,O
18,NUMBER
],O
.,O
TCM,ORGANIZATION
is,O
a,O
helpful,O
treatment,O
option,O
.,O
The,O
current,DATE
study,O
was,O
limited,O
by,O
a,O
number,O
of,O
factors,O
that,O
require,O
further,O
attention,O
.,O
First,ORDINAL
.,O
a,O
small,O
number,O
of,O
COVID,O
‐,O
19,NUMBER
cases,O
were,O
involved,O
in,O
this,O
study,O
.,O
Second,ORDINAL
.,O
laboratory,O
examination,O
results,O
of,O
a,O
number,O
of,O
patients,O
were,O
missed,O
.,O
resulting,O
in,O
incomplete,O
data,O
.,O
In,O
conclusion,O
.,O
compared,O
with,O
patients,O
initially,O
infected,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
Wuhan,CITY
.,O
the,O
symptoms,O
of,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
in,O
Hengyang,CITY
are,O
relatively,O
mild,O
.,O
and,O
the,O
mean,O
time,O
from,O
onset,O
of,O
symptoms,O
to,O
the,O
first,ORDINAL
physician,TITLE
visit,O
and,O
the,O
mean,O
time,O
from,O
hos,O
‐,O
pital,O
admission,O
to,O
confirmed,O
diagnosis,O
are,O
shorter,O
.,O
COVID,O
‐,O
19,NUMBER
pa,O
‐,O
tients,O
in,O
the,O
present,DATE
research,O
have,O
the,O
following,O
characteris,O
‐,O
tics,O
:,O
First,ORDINAL
.,O
in,O
addition,O
to,O
fever,CAUSE_OF_DEATH
and,O
respiratory,O
symptoms,O
.,O
there,O
are,O
other,O
systemic,O
symptoms,O
;,O
second,ORDINAL
.,O
the,O
numbers,O
Zhong,PERSON
ZF,O
et,O
al,O
.,O
Epidemiological,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
of,O
pe,O
‐,O
ripheral,O
blood,O
leukocytes,O
.,O
lymphocytes,O
.,O
and,O
eosinophils,O
are,O
sig,O
‐,O
nificantly,O
reduced,O
.,O
especially,O
the,O
number,O
of,O
eosinophils,O
.,O
which,O
is,O
reduced,O
in,O
all,O
the,O
patients,O
;,O
third,ORDINAL
.,O
some,O
morphological,O
charac,O
‐,O
teristics,O
of,O
pulmonary,O
lesions,O
appeared,O
in,O
the,O
chest,O
CT,STATE_OR_PROVINCE
scan,O
;,O
fourth,ORDINAL
.,O
laboratory,O
tests,O
revealed,O
multiple,O
organ,O
abnormality,O
or,O
damage,O
.,O
Our,O
outcomes,O
may,O
assist,O
clinicians,O
in,O
diagnosis,O
and,O
treatment,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
ARTICLE,O
HIGHLIGHTS,O
Research,O
background,O
At,O
present,DATE
.,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
is,O
influencing,O
210,NUMBER
countries,O
and,O
territories,O
worldwide,O
.,O
which,O
is,O
becoming,O
a,O
severe,O
public,O
health,O
concern,O
.,O
Research,O
motivation,O
There,O
have,O
been,O
rare,O
reports,O
about,O
the,O
differences,O
in,O
the,O
epidemiological,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
with,O
different,O
genders,O
.,O
clinical,O
classification,O
.,O
and,O
with,O
or,O
without,O
basic,O
diseases,CAUSE_OF_DEATH
.,O
Re,O
‐,O
search,O
objectives,O
To,O
study,O
the,O
differences,O
in,O
the,O
epidemiological,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
with,O
different,O
genders,O
.,O
clinical,O
classification,O
.,O
and,O
with,O
or,O
without,O
basic,O
dis,O
‐,O
eases,O
.,O
and,O
provide,O
a,O
reliable,O
reference,O
for,O
the,O
prevention,O
and,O
control,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
Research,O
methods,O
From,O
January,DATE
16,DATE
to,O
March,DATE
2,NUMBER
.,O
2020,DATE
.,O
a,O
total,O
of,O
48,NUMBER
confirmed,O
cases,O
of,O
COVID,O
‐,O
19,NUMBER
have,O
been,O
re,O
‐,O
ported,O
in,O
Hengyang,CITY
and,O
were,O
included,O
in,O
this,O
study,O
.,O
All,O
the,O
data,O
were,O
imported,O
into,O
the,O
excel,O
worksheet,O
and,O
statistically,O
analyzed,O
by,O
using,O
SPSS25,O
.0,NUMBER
software,O
.,O
Research,O
results,O
The,O
main,O
symptoms,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
in,O
Hengyang,CITY
were,O
fever,CAUSE_OF_DEATH
.,O
cough,O
and,O
expectora,O
‐,O
tion,O
.,O
fatigue,O
.,O
and,O
chills,O
.,O
and,O
there,O
were,O
multiple,O
organ,O
dysfunc,O
‐,O
tion,O
or,O
damage,O
.,O
such,O
as,O
reduced,O
peripheral,O
blood,O
leukocytes,O
.,O
lym,O
‐,O
phocytes,O
.,O
and,O
eosinophils,O
.,O
and,O
increased,O
C,O
‐,O
reactive,O
protein,O
.,O
fib,O
‐,O
rinogen,O
.,O
blood,O
glucose,O
.,O
LD,O
‐,O
L,O
.,O
D,O
‐,O
dimer,O
.,O
ALT,O
.,O
AST,ORGANIZATION
.,O
‐,O
GT,O
.,O
MB,STATE_OR_PROVINCE
.,O
and,O
CK,O
.,O
Except,O
for,O
the,O
mild,O
patients,O
.,O
chest,O
CT,STATE_OR_PROVINCE
showed,O
pulmonary,O
lesions,O
.,O
On,O
March,DATE
2,DATE
.,DATE
2020,DATE
.,O
48,NUMBER
patients,O
with,O
COVID,O
‐,O
19,NUMBER
were,O
all,O
cured,O
and,O
discharged,O
.,O
Research,O
conclusions,O
The,O
epidemiological,O
and,O
clini,O
‐,O
cal,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
with,O
different,O
genders,O
.,O
clinical,O
classification,O
.,O
and,O
with,O
or,O
without,O
basic,O
diseases,CAUSE_OF_DEATH
are,O
not,O
very,O
different,O
in,O
most,O
cases,O
.,O
and,O
slightly,O
different,O
in,O
indi,O
‐,O
vidual,O
cases,O
.,O
Clinical,O
manifestations,O
and,O
laboratory,O
tests,O
reveal,O
that,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
have,O
multiple,O
organ,O
dysfunction,O
or,O
damage,O
.,O
Research,O
perspectives,O
The,O
mechanism,O
of,O
COVID,O
‐,O
19,NUMBER
combin,O
‐,O
ing,O
multiple,O
organ,O
dysfunction,O
or,O
damage,O
is,O
worth,O
further,O
Lu,PERSON
H,PERSON
.,O
Stratton,ORGANIZATION
CW,ORGANIZATION
.,O
Tang,PERSON
YW,O
.,O
Outbreak,O
of,O
pneumonia,CAUSE_OF_DEATH
of,O
unknown,O
etiology,O
in,O
Wuhan,CITY
.,O
China,COUNTRY
:,O
The,O
Zhu,PERSON
N,PERSON
.,O
Zhang,PERSON
D,PERSON
.,O
Wang,PERSON
W,PERSON
.,O
Li,PERSON
X,PERSON
.,O
Yang,PERSON
B,O
.,O
Song,O
J,O
.,O
Zhao,PERSON
X,PERSON
.,O
Huang,PERSON
B,PERSON
.,O
Shi,PERSON
W,PERSON
.,O
Lu,PERSON
R,PERSON
.,O
Niu,PERSON
P,O
.,O
Zhan,PERSON
F,PERSON
.,O
Ma,PERSON
X,PERSON
.,O
Wang,PERSON
D,O
.,O
Xu,PERSON
W,O
.,O
Wu,PERSON
G,PERSON
.,O
Gao,PERSON
GF,PERSON
.,O
Tan,O
W,O
;,O
China,COUNTRY
Novel,O
Coronavirus,O
Investigating,O
and,O
Research,ORGANIZATION
Team,ORGANIZATION
.,O
A,O
Novel,MISC
Coronavirus,MISC
from,O
Patients,O
with,O
Pneumonia,CAUSE_OF_DEATH
in,O
China,COUNTRY
.,O
2019,DATE
.,O
N,O
Engl,O
J,O
Med,O
2020,DATE
;,O
382,NUMBER
:,O
727,NUMBER
‐,O
733,NUMBER
Gostic,O
K,O
.,O
Gomez,PERSON
AC,ORGANIZATION
.,O
Mummah,PERSON
RO,PERSON
.,O
Kucharski,PERSON
AJ,PERSON
.,O
Lloyd,PERSON
‐,PERSON
Smith,PERSON
JO,PERSON
.,O
Estimated,O
effective,O
‐,O
ness,O
of,O
symptom,O
Cao,PERSON
J,PERSON
.,O
Tu,O
WJ,O
.,O
Cheng,PERSON
W,PERSON
.,O
Yu,PERSON
L,PERSON
.,O
Liu,PERSON
YK,O
.,O
Hu,PERSON
X,PERSON
.,O
Liu,PERSON
Q.,O
Clinical,O
Features,O
and,O
Short,O
‐,O
term,O
Outcomes,O
of,O
102,NUMBER
Huang,PERSON
C,PERSON
.,O
Wang,O
Y,O
.,O
Li,PERSON
X,PERSON
.,O
Ren,PERSON
L,PERSON
.,O
Zhao,PERSON
J,PERSON
.,O
Hu,O
Y,O
.,O
Zhang,PERSON
L,PERSON
.,O
Fan,O
G,O
.,O
Xu,PERSON
J,PERSON
.,O
Gu,O
X,O
.,O
Cheng,PERSON
Z,PERSON
.,O
Yu,PERSON
T,PERSON
.,O
Xia,PERSON
J,PERSON
.,O
Wei,O
Y,O
.,O
Wu,PERSON
W,PERSON
.,O
Xie,PERSON
X,PERSON
.,O
Yin,PERSON
W,PERSON
.,O
Li,PERSON
H,PERSON
.,O
Liu,PERSON
M,O
.,O
Xiao,PERSON
Y,PERSON
.,O
Gao,PERSON
H,O
.,O
Guo,PERSON
L,PERSON
.,O
Xie,PERSON
J,PERSON
.,O
Wang,PERSON
G,PERSON
.,O
Jiang,PERSON
R,PERSON
.,O
Gao,PERSON
Z,PERSON
.,O
Jin,PERSON
Q,O
.,O
Wang,PERSON
J,PERSON
.,O
Cao,PERSON
B.,PERSON
Clinical,O
features,O
of,O
patients,O
infected,O
with,O
2019,DATE
novel,O
coron,O
‐,O
avirus,O
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
Guan,O
WJ,O
.,O
Ni,O
ZY,O
.,O
Hu,O
Y,O
.,O
Liang,PERSON
WH,PERSON
.,O
Ou,O
CQ,O
.,O
He,O
JX,O
.,O
Liu,PERSON
L,PERSON
.,O
Shan,O
H,O
.,O
Lei,O
CL,O
.,O
Hui,O
DSC,ORGANIZATION
.,O
Du,O
B,O
.,O
Li,PERSON
LJ,PERSON
.,O
Zeng,PERSON
G,PERSON
.,O
Yuen,PERSON
KY,STATE_OR_PROVINCE
.,O
Chen,PERSON
RC,O
.,O
Tang,ORGANIZATION
CL,ORGANIZATION
.,O
Wang,PERSON
T,O
.,O
Chen,PERSON
PY,PERSON
.,O
Xiang,PERSON
J,PERSON
.,O
Li,PERSON
SY,PERSON
.,O
Wang,O
JL,O
.,O
Liang,PERSON
ZJ,PERSON
.,O
Peng,PERSON
YX,PERSON
.,O
Wei,PERSON
L,PERSON
.,O
Liu,PERSON
Y,O
.,O
Hu,O
YH,O
.,O
Peng,PERSON
P,PERSON
.,O
Wang,PERSON
JM,PERSON
.,O
Liu,PERSON
JY,PERSON
.,O
Chen,O
Z,O
.,O
Li,PERSON
G,PERSON
.,O
Zheng,PERSON
ZJ,PERSON
.,O
Qiu,PERSON
SQ,O
.,O
Luo,PERSON
J,PERSON
.,O
Ye,PERSON
CJ,PERSON
.,O
Zhu,PERSON
SY,PERSON
.,O
Zhong,PERSON
NS,STATE_OR_PROVINCE
;,O
China,ORGANIZATION
Medical,ORGANIZATION
Treatment,ORGANIZATION
Expert,ORGANIZATION
Group,ORGANIZATION
for,O
Covid,O
‐,O
19,NUMBER
.,O
Clinical,O
Char,PERSON
‐,PERSON
acteristics,O
of,O
Coronavirus,O
Released,O
by,O
National,ORGANIZATION
Health,ORGANIZATION
Commission,ORGANIZATION
National,ORGANIZATION
Administration,ORGANIZATION
of,ORGANIZATION
Traditional,ORGANIZATION
Chinese,ORGANIZATION
Medicine,ORGANIZATION
on,O
March,DATE
3,NUMBER
.,O
2020,DATE
.,O
Diagnosis,O
and,O
Treatment,O
Protocol,O
for,O
Novel,O
Coronavirus,O
Pneumonia,CAUSE_OF_DEATH
(,O
Trial,O
Version,O
Zhong,O
ZF,O
et,O
al,O
.,O
Epidemiological,O
and,O
clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
Wang,O
D,O
.,O
Hu,O
B,O
.,O
Hu,O
C,O
.,O
Zhu,PERSON
F,O
.,O
Liu,PERSON
X,PERSON
.,O
Zhang,PERSON
J,PERSON
.,O
Wang,O
B,O
.,O
Xiang,PERSON
H,O
.,O
Cheng,PERSON
Z,PERSON
.,O
Xiong,PERSON
Y,PERSON
.,O
Zhao,PERSON
Y,PERSON
.,O
Li,PERSON
Y,PERSON
.,O
Wang,PERSON
X,PERSON
.,O
Peng,PERSON
Z.,O
Clinical,O
Characteristics,O
of,O
138,NUMBER
Hospitalized,O
Pa,STATE_OR_PROVINCE
‐,O
tients,O
With,O
2019,DATE
Novel,MISC
Coronavirus,MISC
‐,O
Infected,O
Epidemiology,O
Working,O
Group,O
for,O
NCIP,ORGANIZATION
Epidemic,ORGANIZATION
Response,ORGANIZATION
.,O
Chinese,NATIONALITY
Center,O
for,O
Disease,CAUSE_OF_DEATH
Con,O
‐,O
trol,O
and,O
Prevention,O
.,O
The,O
epidemiological,O
characteristics,O
of,O
an,O
outbreak,O
of,O
2019,DATE
novel,O
coronavirus,O
diseases,CAUSE_OF_DEATH
Special,O
Expert,O
Group,O
for,O
Control,O
of,O
the,O
Epidemic,O
of,O
Novel,O
Coronavirus,O
Pneumonia,CAUSE_OF_DEATH
of,O
the,O
Chinese,ORGANIZATION
Preventive,ORGANIZATION
Medicine,ORGANIZATION
Association,ORGANIZATION
.,O
An,O
update,O
on,O
the,O
epi,O
‐,O
demiological,O
characteristics,O
of,O
novel,O
coronavirus,O
Li,O
Q,O
.,O
Guan,O
X,O
.,O
Wu,O
P,O
.,O
Wang,PERSON
X,PERSON
.,O
Zhou,PERSON
L,PERSON
.,O
Tong,O
Y,O
.,O
Ren,PERSON
R,PERSON
.,O
Leung,LOCATION
KSM,LOCATION
.,O
Lau,LOCATION
EHY,LOCATION
.,O
Wong,PERSON
JY,PERSON
.,O
Xing,PERSON
X,PERSON
.,O
Xiang,PERSON
N,PERSON
.,O
Wu,O
Y,O
.,O
Li,PERSON
C,PERSON
.,O
Chen,PERSON
Q,O
.,O
Li,PERSON
D,PERSON
.,O
Liu,PERSON
T,PERSON
.,O
Zhao,PERSON
J,PERSON
.,O
Liu,PERSON
M,O
.,O
Tu,O
W,O
.,O
Chen,PERSON
C,PERSON
.,O
Jin,PERSON
L,PERSON
.,O
Yang,PERSON
R,PERSON
.,O
Wang,O
Q,O
.,O
Zhou,PERSON
S,PERSON
.,O
Wang,PERSON
R,PERSON
.,O
Liu,PERSON
H,PERSON
.,O
Luo,PERSON
Y,O
.,O
Liu,PERSON
Y,PERSON
.,O
Shao,PERSON
G,PERSON
.,O
Li,PERSON
H,PERSON
.,O
Tao,O
Z,O
.,O
Yang,PERSON
Y,PERSON
.,O
Deng,PERSON
Z,PERSON
.,O
Liu,PERSON
B,PERSON
.,O
Ma,PERSON
Z,PERSON
.,O
Zhang,PERSON
Y,O
.,O
Shi,PERSON
G,PERSON
.,O
Lam,ORGANIZATION
TTY,ORGANIZATION
.,O
Wu,PERSON
JT,PERSON
.,O
Gao,PERSON
GF,PERSON
.,O
Cowling,O
BJ,O
.,O
Yang,PERSON
B,PERSON
.,O
Leung,PERSON
GM,O
.,O
Feng,ORGANIZATION
Z.,ORGANIZATION
Early,ORGANIZATION
Transmission,ORGANIZATION
Dynamics,ORGANIZATION
in,ORGANIZATION
Wong,ORGANIZATION
SC,ORGANIZATION
.,O
Kwong,ORGANIZATION
RT,ORGANIZATION
.,O
Wu,PERSON
TC,PERSON
.,O
Chan,RELIGION
JWM,O
.,O
Chu,O
MY,O
.,O
Lee,PERSON
SY,PERSON
.,O
Wong,PERSON
HY,PERSON
.,O
Lung,O
DC,STATE_OR_PROVINCE
.,O
Risk,O
of,O
nosocomial,O
transmission,O
of,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
:,O
an,O
experience,O
in,O
a,O
gen,O
‐,O
eral,O
ward,O
setting,O
in,O
Hong,CITY
Kong,CITY
.,O
J,PERSON
Hosp,PERSON
Zhang,PERSON
C,PERSON
.,O
Shi,PERSON
L,PERSON
.,O
Wang,O
FS,O
.,O
Liver,O
injury,O
in,O
COVID,O
‐,O
19,NUMBER
:,O
management,O
and,O
challenges,O
.,O
Lancet,O
Gas,O
‐,O
troenterol,O
Chau,O
TN,STATE_OR_PROVINCE
.,O
Lee,PERSON
KC,PERSON
.,O
Yao,PERSON
H,PERSON
.,O
Tsang,PERSON
TY,PERSON
.,O
Chow,ORGANIZATION
TC,ORGANIZATION
.,O
Yeung,PERSON
YC,PERSON
.,O
Choi,PERSON
KW,PERSON
.,O
Tso,PERSON
YK,PERSON
.,O
Lau,PERSON
T,O
.,O
Lai,O
ST,O
.,O
Lai,O
CL,O
.,O
SARS,O
‐,O
associated,O
viral,O
hepatitis,O
caused,O
by,O
a,O
novel,O
coronavirus,O
:,O
report,O
of,O
three,NUMBER
cases,O
.,O
Hepatology,O
2004,DATE
;,O
39,NUMBER
:,O
Young,O
BE,O
.,O
Ong,LOCATION
SWX,LOCATION
.,O
Kalimuddin,PERSON
S,O
.,O
Low,O
JG,O
.,O
Tan,PERSON
SY,O
.,O
Loh,PERSON
J,PERSON
.,O
Ng,O
OT,O
.,O
Marimuthu,PERSON
K,PERSON
.,O
Ang,PERSON
LW,PERSON
.,O
Mak,PERSON
TM,O
.,O
Lau,PERSON
SK,STATE_OR_PROVINCE
.,O
Anderson,PERSON
DE,STATE_OR_PROVINCE
.,O
Chan,PERSON
KS,PERSON
.,O
Tan,LOCATION
TY,LOCATION
.,O
Ng,PERSON
TY,PERSON
.,O
Cui,PERSON
L,PERSON
.,O
Said,O
Z,O
.,O
Kurupatham,O
L,O
.,O
Chen,PERSON
MI,PERSON
.,O
Chan,RELIGION
M,O
.,O
Vasoo,PERSON
S,PERSON
.,O
Wang,O
LF,O
.,O
Tan,O
BH,O
.,O
Lin,PERSON
RTP,O
.,O
Lee,PERSON
VJM,PERSON
.,O
Leo,PERSON
YS,O
.,O
Lye,PERSON
DC,STATE_OR_PROVINCE
;,O
Singapore,COUNTRY
2019,DATE
Novel,O
Coronavirus,O
Lee,O
EYP,O
.,O
Ng,O
MY,O
.,O
Khong,ORGANIZATION
PL,ORGANIZATION
.,O
COVID,O
‐,O
19,NUMBER
pneumonia,CAUSE_OF_DEATH
:,O
what,O
has,O
CT,STATE_OR_PROVINCE
taught,O
us,O
?,O
Lancet,O
Infect,O
Dis,PERSON
2020,DATE
;,O
20,NUMBER
:,O
Sanders,O
JM,O
.,O
Monogue,ORGANIZATION
ML,ORGANIZATION
.,O
Jodlowski,PERSON
TZ,PERSON
.,O
Cutrell,O
JB,O
.,O
Phar,O
‐,O
macologic,O
Treatments,O
for,O
Coronavirus,O
7041,NUMBER
Koll,LOCATION
Center,LOCATION
Parkway,LOCATION
.,O
Suite,O
160,NUMBER
.,O
Pleasanton,CITY
.,O
CA,STATE_OR_PROVINCE
94566,NUMBER
.,O
USA,COUNTRY
